id	sid	tid	token	lemma	pos
chd-110	1	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-110	1	2	e1	e1	NOUN
chd-110	1	3	cancer	cancer	NOUN
chd-110	1	4	health	health	NOUN
chd-110	1	5	disparities	disparity	NOUN
chd-110	1	6	research	research	VERB
chd-110	1	7	quality	quality	NOUN
chd-110	1	8	of	of	ADP
chd-110	1	9	evidence	evidence	NOUN
chd-110	1	10	on	on	ADP
chd-110	1	11	prostate	prostate	NOUN
chd-110	1	12	cancer	cancer	NOUN
chd-110	1	13	in	in	ADP
chd-110	1	14	nigeria	nigeria	PROPN
chd-110	1	15	omolara	omolara	PROPN
chd-110	1	16	aminat	aminat	ADJ
chd-110	1	17	fatiregun*1,2	fatiregun*1,2	PROPN
chd-110	1	18	,	,	PUNCT
chd-110	1	19	frank	frank	PROPN
chd-110	1	20	chinegwundoh1,3	chinegwundoh1,3	PROPN
chd-110	1	21	,	,	PUNCT
chd-110	1	22	proffessor	proffessor	NOUN
chd-110	1	23	nicholas	nicholas	PROPN
chd-110	1	24	d	d	PROPN
chd-110	1	25	james1,4	james1,4	PROPN
chd-110	1	26	,	,	PUNCT
chd-110	1	27	odunayo	odunayo	VERB
chd-110	1	28	ikuerowo1,5	ikuerowo1,5	PROPN
chd-110	1	29	,	,	PUNCT
chd-110	1	30	olufunmilade	olufunmilade	NOUN
chd-110	1	31	omisanjo1,5	omisanjo1,5	PROPN
chd-110	1	32	,	,	PUNCT
chd-110	1	33	abimbola	abimbola	PROPN
chd-110	1	34	abolarinwa1,5	abolarinwa1,5	PROPN
chd-110	1	35	,	,	PUNCT
chd-110	1	36	anthonia	anthonia	NOUN
chd-110	1	37	chima	chima	PROPN
chd-110	1	38	sowunmi1,6	sowunmi1,6	PROPN
chd-110	1	39	,	,	PUNCT
chd-110	1	40	funlayo	funlayo	PROPN
chd-110	1	41	buraimoh1,7	buraimoh1,7	PROPN
chd-110	1	42	,	,	PUNCT
chd-110	1	43	folakemi	folakemi	NOUN
chd-110	1	44	odedina1	odedina1	PROPN
chd-110	1	45	,	,	PUNCT
chd-110	1	46	8	8	NUM
chd-110	1	47	1	1	NUM
chd-110	1	48	prostate	prostate	NOUN
chd-110	1	49	cancer	cancer	NOUN
chd-110	1	50	transatlantic	transatlantic	ADJ
chd-110	1	51	consortium,2	consortium,2	ADJ
chd-110	1	52	oncology	oncology	NOUN
chd-110	1	53	unit	unit	NOUN
chd-110	1	54	,	,	PUNCT
chd-110	1	55	department	department	NOUN
chd-110	1	56	of	of	ADP
chd-110	1	57	radiology	radiology	NOUN
chd-110	1	58	,	,	PUNCT
chd-110	1	59	lagos	lagos	NOUN
chd-110	1	60	state	state	PROPN
chd-110	1	61	university	university	PROPN
chd-110	1	62	college	college	NOUN
chd-110	1	63	of	of	ADP
chd-110	1	64	medicine	medicine	NOUN
chd-110	1	65	,	,	PUNCT
chd-110	1	66	ikeja	ikeja	NOUN
chd-110	1	67	,	,	PUNCT
chd-110	1	68	lagos	lago	NOUN
chd-110	1	69	,	,	PUNCT
chd-110	1	70	nigeria	nigeria	PROPN
chd-110	1	71	3	3	NUM
chd-110	1	72	department	department	NOUN
chd-110	1	73	of	of	ADP
chd-110	1	74	urology	urology	NOUN
chd-110	1	75	,	,	PUNCT
chd-110	1	76	barts	bart	NOUN
chd-110	1	77	health	health	NOUN
chd-110	1	78	,	,	PUNCT
chd-110	1	79	national	national	PROPN
chd-110	1	80	health	health	PROPN
chd-110	1	81	service	service	PROPN
chd-110	1	82	trust	trust	PROPN
chd-110	1	83	,	,	PUNCT
chd-110	1	84	london	london	PROPN
chd-110	1	85	4	4	NUM
chd-110	1	86	university	university	NOUN
chd-110	1	87	hospitals	hospital	NOUN
chd-110	1	88	birmingham	birmingham	PROPN
chd-110	1	89	nhs	nhs	PROPN
chd-110	1	90	foundation	foundation	PROPN
chd-110	1	91	trust	trust	PROPN
chd-110	1	92	,	,	PUNCT
chd-110	1	93	the	the	DET
chd-110	1	94	medical	medical	ADJ
chd-110	1	95	school	school	NOUN
chd-110	1	96	,	,	PUNCT
chd-110	1	97	university	university	NOUN
chd-110	1	98	of	of	ADP
chd-110	1	99	birmingham	birmingham	PROPN
chd-110	1	100	,	,	PUNCT
chd-110	1	101	birmingham	birmingham	PROPN
chd-110	1	102	,	,	PUNCT
chd-110	1	103	uk	uk	PROPN
chd-110	1	104	5	5	NUM
chd-110	1	105	department	department	NOUN
chd-110	1	106	of	of	ADP
chd-110	1	107	surgery	surgery	NOUN
chd-110	1	108	,	,	PUNCT
chd-110	1	109	lagos	lagos	NOUN
chd-110	1	110	state	state	PROPN
chd-110	1	111	university	university	PROPN
chd-110	1	112	college	college	NOUN
chd-110	1	113	of	of	ADP
chd-110	1	114	medicine/	medicine/	NUM
chd-110	1	115	lagos	lagos	PROPN
chd-110	1	116	state	state	NOUN
chd-110	1	117	university	university	PROPN
chd-110	1	118	teaching	teaching	NOUN
chd-110	1	119	hospital	hospital	NOUN
chd-110	1	120	,	,	PUNCT
chd-110	1	121	ikeja	ikeja	NOUN
chd-110	1	122	,	,	PUNCT
chd-110	1	123	lagos	lago	NOUN
chd-110	1	124	,	,	PUNCT
chd-110	1	125	nigeria	nigeria	PROPN
chd-110	1	126	6	6	NUM
chd-110	1	127	department	department	NOUN
chd-110	1	128	of	of	ADP
chd-110	1	129	radiotherapy	radiotherapy	PROPN
chd-110	1	130	&	&	CCONJ
chd-110	1	131	oncology	oncology	NOUN
chd-110	1	132	,	,	PUNCT
chd-110	1	133	lagos	lagos	NOUN
chd-110	1	134	university	university	NOUN
chd-110	1	135	teaching	teach	VERB
chd-110	1	136	hospital/	hospital/	NUM
chd-110	1	137	university	university	NOUN
chd-110	1	138	of	of	ADP
chd-110	1	139	lagos	lago	NOUN
chd-110	1	140	,	,	PUNCT
chd-110	1	141	lagos	lago	NOUN
chd-110	1	142	,	,	PUNCT
chd-110	1	143	nigeria	nigeria	PROPN
chd-110	1	144	.	.	PUNCT
chd-110	2	1	7department	7department	NUM
chd-110	2	2	of	of	ADP
chd-110	2	3	biochemistry	biochemistry	NOUN
chd-110	2	4	,	,	PUNCT
chd-110	2	5	lagos	lagos	NOUN
chd-110	2	6	state	state	PROPN
chd-110	2	7	university	university	PROPN
chd-110	2	8	college	college	NOUN
chd-110	2	9	of	of	ADP
chd-110	2	10	medicine	medicine	NOUN
chd-110	2	11	.	.	PUNCT
chd-110	3	1	8	8	NUM
chd-110	3	2	department	department	NOUN
chd-110	3	3	of	of	ADP
chd-110	3	4	pharmacotherapy	pharmacotherapy	NOUN
chd-110	3	5	and	and	CCONJ
chd-110	3	6	translational	translational	ADJ
chd-110	3	7	research	research	NOUN
chd-110	3	8	and	and	CCONJ
chd-110	3	9	department	department	NOUN
chd-110	3	10	of	of	ADP
chd-110	3	11	radiation	radiation	NOUN
chd-110	3	12	oncology	oncology	NOUN
chd-110	3	13	,	,	PUNCT
chd-110	3	14	university	university	PROPN
chd-110	3	15	of	of	ADP
chd-110	3	16	florida	florida	PROPN
chd-110	3	17	,	,	PUNCT
chd-110	3	18	lake	lake	PROPN
chd-110	3	19	nona	nona	PROPN
chd-110	3	20	campus	campus	PROPN
chd-110	3	21	,	,	PUNCT
chd-110	3	22	fl	fl	PROPN
chd-110	3	23	,	,	PUNCT
chd-110	3	24	32832	32832	NUM
chd-110	3	25	,	,	PUNCT
chd-110	3	26	usa	usa	PROPN
chd-110	3	27	*	*	PUNCT
chd-110	3	28	corresponding	correspond	VERB
chd-110	3	29	author	author	NOUN
chd-110	3	30	email	email	NOUN
chd-110	3	31	:	:	PUNCT
chd-110	3	32	omolarafatiregun@gmail.com	omolarafatiregun@gmail.com	X
chd-110	3	33	.	.	PUNCT
chd-110	3	34	prostate	prostate	NOUN
chd-110	3	35	cancer	cancer	NOUN
chd-110	3	36	is	be	AUX
chd-110	3	37	the	the	DET
chd-110	3	38	2nd	2nd	ADJ
chd-110	3	39	commonest	commonest	NOUN
chd-110	3	40	malignancy	malignancy	NOUN
chd-110	3	41	in	in	ADP
chd-110	3	42	men	man	NOUN
chd-110	3	43	worldwide	worldwide	ADV
chd-110	3	44	.	.	PUNCT
chd-110	4	1	it	it	PRON
chd-110	4	2	is	be	AUX
chd-110	4	3	,	,	PUNCT
chd-110	4	4	however	however	ADV
chd-110	4	5	,	,	PUNCT
chd-110	4	6	the	the	DET
chd-110	4	7	commonest	commonest	NOUN
chd-110	4	8	in	in	ADP
chd-110	4	9	nigeria	nigeria	PROPN
chd-110	4	10	.	.	PUNCT
chd-110	5	1	while	while	SCONJ
chd-110	5	2	several	several	ADJ
chd-110	5	3	disparities	disparity	NOUN
chd-110	5	4	have	have	AUX
chd-110	5	5	been	be	AUX
chd-110	5	6	documented	document	VERB
chd-110	5	7	between	between	ADP
chd-110	5	8	caucasian	caucasian	ADJ
chd-110	5	9	men	man	NOUN
chd-110	5	10	and	and	CCONJ
chd-110	5	11	men	man	NOUN
chd-110	5	12	of	of	ADP
chd-110	5	13	african	african	ADJ
chd-110	5	14	descent	descent	NOUN
chd-110	5	15	,	,	PUNCT
chd-110	5	16	there	there	PRON
chd-110	5	17	is	be	VERB
chd-110	5	18	limited	limited	ADJ
chd-110	5	19	research	research	NOUN
chd-110	5	20	on	on	ADP
chd-110	5	21	prostate	prostate	NOUN
chd-110	5	22	cancer	cancer	NOUN
chd-110	5	23	in	in	ADP
chd-110	5	24	nigeria	nigeria	PROPN
chd-110	5	25	.	.	PUNCT
chd-110	6	1	evidence	evidence	NOUN
chd-110	6	2	based	base	VERB
chd-110	6	3	medicine	medicine	NOUN
chd-110	6	4	is	be	AUX
chd-110	6	5	a	a	DET
chd-110	6	6	key	key	ADJ
chd-110	6	7	tool	tool	NOUN
chd-110	6	8	in	in	ADP
chd-110	6	9	making	make	VERB
chd-110	6	10	clinical	clinical	ADJ
chd-110	6	11	decisions	decision	NOUN
chd-110	6	12	and	and	CCONJ
chd-110	6	13	developing	develop	VERB
chd-110	6	14	screening	screening	NOUN
chd-110	6	15	and	and	CCONJ
chd-110	6	16	treatment	treatment	NOUN
chd-110	6	17	guidelines	guideline	NOUN
chd-110	6	18	.	.	PUNCT
chd-110	7	1	this	this	DET
chd-110	7	2	review	review	NOUN
chd-110	7	3	was	be	AUX
chd-110	7	4	undertaken	undertake	VERB
chd-110	7	5	to	to	PART
chd-110	7	6	assess	assess	VERB
chd-110	7	7	the	the	DET
chd-110	7	8	levels	level	NOUN
chd-110	7	9	of	of	ADP
chd-110	7	10	evidence	evidence	NOUN
chd-110	7	11	on	on	ADP
chd-110	7	12	prostate	prostate	NOUN
chd-110	7	13	cancer	cancer	NOUN
chd-110	7	14	research	research	NOUN
chd-110	7	15	in	in	ADP
chd-110	7	16	nigeria	nigeria	PROPN
chd-110	7	17	.	.	PUNCT
chd-110	8	1	a	a	DET
chd-110	8	2	systematic	systematic	ADJ
chd-110	8	3	review	review	NOUN
chd-110	8	4	of	of	ADP
chd-110	8	5	all	all	DET
chd-110	8	6	research	research	NOUN
chd-110	8	7	published	publish	VERB
chd-110	8	8	on	on	ADP
chd-110	8	9	prostate	prostate	NOUN
chd-110	8	10	cancer	cancer	NOUN
chd-110	8	11	from	from	ADP
chd-110	8	12	january	january	PROPN
chd-110	8	13	1975	1975	NUM
chd-110	8	14	to	to	PART
chd-110	8	15	may	may	PROPN
chd-110	8	16	2018	2018	NUM
chd-110	8	17	in	in	ADP
chd-110	8	18	nigeria	nigeria	PROPN
chd-110	8	19	was	be	AUX
chd-110	8	20	conducted	conduct	VERB
chd-110	8	21	.	.	PUNCT
chd-110	9	1	we	we	PRON
chd-110	9	2	reviewed	review	VERB
chd-110	9	3	all	all	DET
chd-110	9	4	articles	article	NOUN
chd-110	9	5	found	find	VERB
chd-110	9	6	on	on	ADP
chd-110	9	7	various	various	ADJ
chd-110	9	8	databases	database	NOUN
chd-110	9	9	by	by	ADP
chd-110	9	10	searching	search	VERB
chd-110	9	11	for	for	ADP
chd-110	9	12	“	"	PUNCT
chd-110	9	13	prostate	prostate	NOUN
chd-110	9	14	cancer	cancer	NOUN
chd-110	9	15	in	in	ADP
chd-110	9	16	nigeria	nigeria	PROPN
chd-110	9	17	”	"	PUNCT
chd-110	9	18	.	.	PUNCT
chd-110	10	1	we	we	PRON
chd-110	10	2	classified	classify	VERB
chd-110	10	3	them	they	PRON
chd-110	10	4	based	base	VERB
chd-110	10	5	on	on	ADP
chd-110	10	6	their	their	PRON
chd-110	10	7	study	study	NOUN
chd-110	10	8	designs	design	NOUN
chd-110	10	9	into	into	ADP
chd-110	10	10	different	different	ADJ
chd-110	10	11	levels	level	NOUN
chd-110	10	12	of	of	ADP
chd-110	10	13	evidence	evidence	NOUN
chd-110	10	14	as	as	ADV
chd-110	10	15	well	well	ADV
chd-110	10	16	as	as	ADP
chd-110	10	17	year	year	NOUN
chd-110	10	18	of	of	ADP
chd-110	10	19	publication	publication	NOUN
chd-110	10	20	.	.	PUNCT
chd-110	11	1	meta	meta	VERB
chd-110	11	2	-	-	PUNCT
chd-110	11	3	analyses	analysis	NOUN
chd-110	11	4	were	be	AUX
chd-110	11	5	not	not	PART
chd-110	11	6	considered	consider	VERB
chd-110	11	7	in	in	ADP
chd-110	11	8	the	the	DET
chd-110	11	9	review	review	NOUN
chd-110	11	10	.	.	PUNCT
chd-110	12	1	a	a	DET
chd-110	12	2	total	total	NOUN
chd-110	12	3	of	of	ADP
chd-110	12	4	171	171	NUM
chd-110	12	5	articles	article	NOUN
chd-110	12	6	were	be	AUX
chd-110	12	7	eligible	eligible	ADJ
chd-110	12	8	for	for	ADP
chd-110	12	9	this	this	DET
chd-110	12	10	review	review	NOUN
chd-110	12	11	.	.	PUNCT
chd-110	13	1	most	most	ADJ
chd-110	13	2	publications	publication	NOUN
chd-110	13	3	were	be	AUX
chd-110	13	4	at	at	ADP
chd-110	13	5	the	the	DET
chd-110	13	6	4th	4th	ADJ
chd-110	13	7	(	(	PUNCT
chd-110	13	8	66	66	NUM
chd-110	13	9	%	%	NOUN
chd-110	13	10	)	)	PUNCT
chd-110	13	11	and	and	CCONJ
chd-110	13	12	5th	5th	ADJ
chd-110	13	13	levels	level	NOUN
chd-110	13	14	of	of	ADP
chd-110	13	15	evidence	evidence	NOUN
chd-110	13	16	(	(	PUNCT
chd-110	13	17	17	17	NUM
chd-110	13	18	%	%	NOUN
chd-110	13	19	)	)	PUNCT
chd-110	13	20	respectively	respectively	ADV
chd-110	13	21	.	.	PUNCT
chd-110	14	1	no	no	DET
chd-110	14	2	clinical	clinical	ADJ
chd-110	14	3	trials	trial	NOUN
chd-110	14	4	on	on	ADP
chd-110	14	5	prostate	prostate	NOUN
chd-110	14	6	cancer	cancer	NOUN
chd-110	14	7	in	in	ADP
chd-110	14	8	nigeria	nigeria	PROPN
chd-110	14	9	was	be	AUX
chd-110	14	10	seen	see	VERB
chd-110	14	11	or	or	CCONJ
chd-110	14	12	registered	register	VERB
chd-110	14	13	on	on	ADP
chd-110	14	14	clinicaltrials.gov	clinicaltrials.gov	NOUN
chd-110	14	15	,	,	PUNCT
chd-110	14	16	hence	hence	ADV
chd-110	14	17	no	no	DET
chd-110	14	18	studies	study	NOUN
chd-110	14	19	at	at	ADP
chd-110	14	20	level	level	NOUN
chd-110	14	21	1	1	NUM
chd-110	14	22	(	(	PUNCT
chd-110	14	23	a	a	DET
chd-110	14	24	,	,	PUNCT
chd-110	14	25	b	b	NOUN
chd-110	14	26	or	or	CCONJ
chd-110	14	27	c	c	NOUN
chd-110	14	28	)	)	PUNCT
chd-110	14	29	of	of	ADP
chd-110	14	30	evidence	evidence	NOUN
chd-110	14	31	published	publish	VERB
chd-110	14	32	in	in	ADP
chd-110	14	33	nigeria	nigeria	PROPN
chd-110	14	34	.	.	PUNCT
chd-110	15	1	the	the	DET
chd-110	15	2	commonest	commonest	NOUN
chd-110	15	3	type	type	NOUN
chd-110	15	4	of	of	ADP
chd-110	15	5	study	study	NOUN
chd-110	15	6	design	design	NOUN
chd-110	15	7	was	be	AUX
chd-110	15	8	cross	cross	ADJ
chd-110	15	9	-	-	ADJ
chd-110	15	10	sectional	sectional	ADJ
chd-110	15	11	studies	study	NOUN
chd-110	15	12	accounting	account	VERB
chd-110	15	13	for	for	ADP
chd-110	15	14	56	56	NUM
chd-110	15	15	%	%	NOUN
chd-110	15	16	of	of	ADP
chd-110	15	17	all	all	DET
chd-110	15	18	publications	publication	NOUN
chd-110	15	19	.	.	PUNCT
chd-110	16	1	prostate	prostate	NOUN
chd-110	16	2	cancer	cancer	NOUN
chd-110	16	3	research	research	NOUN
chd-110	16	4	is	be	AUX
chd-110	16	5	currently	currently	ADV
chd-110	16	6	at	at	ADP
chd-110	16	7	low	low	ADJ
chd-110	16	8	levels	level	NOUN
chd-110	16	9	of	of	ADP
chd-110	16	10	evidence	evidence	NOUN
chd-110	16	11	in	in	ADP
chd-110	16	12	nigeria	nigeria	PROPN
chd-110	16	13	.	.	PUNCT
chd-110	17	1	it	it	PRON
chd-110	17	2	is	be	AUX
chd-110	17	3	pertinent	pertinent	ADJ
chd-110	17	4	to	to	PART
chd-110	17	5	explore	explore	VERB
chd-110	17	6	and	and	CCONJ
chd-110	17	7	increase	increase	VERB
chd-110	17	8	funding	funding	NOUN
chd-110	17	9	channels	channel	NOUN
chd-110	17	10	for	for	ADP
chd-110	17	11	cancer	cancer	NOUN
chd-110	17	12	related	relate	VERB
chd-110	17	13	research	research	NOUN
chd-110	17	14	.	.	PUNCT
chd-110	18	1	keywords	keyword	NOUN
chd-110	18	2	:	:	PUNCT
chd-110	18	3	prostate	prostate	NOUN
chd-110	18	4	,	,	PUNCT
chd-110	18	5	cancer	cancer	NOUN
chd-110	18	6	,	,	PUNCT
chd-110	18	7	nigeria	nigeria	PROPN
chd-110	18	8	.	.	PUNCT
chd-110	19	1	citation	citation	NOUN
chd-110	19	2	:	:	PUNCT
chd-110	19	3	fatiregun	fatiregun	NOUN
chd-110	19	4	et	et	PROPN
chd-110	19	5	al	al	PROPN
chd-110	19	6	(	(	PUNCT
chd-110	19	7	2019	2019	NUM
chd-110	19	8	)	)	PUNCT
chd-110	19	9	quality	quality	NOUN
chd-110	19	10	of	of	ADP
chd-110	19	11	evidence	evidence	NOUN
chd-110	19	12	on	on	ADP
chd-110	19	13	prostate	prostate	NOUN
chd-110	19	14	cancer	cancer	NOUN
chd-110	19	15	in	in	ADP
chd-110	19	16	nigeria	nigeria	PROPN
chd-110	19	17	.	.	PUNCT
chd-110	20	1	cancer	cancer	NOUN
chd-110	20	2	health	health	NOUN
chd-110	20	3	disparities	disparity	NOUN
chd-110	20	4	.	.	PUNCT
chd-110	21	1	4	4	NUM
chd-110	21	2	:	:	PUNCT
chd-110	21	3	e1	e1	NOUN
chd-110	21	4	-	-	PUNCT
chd-110	21	5	e9	e9	PROPN
chd-110	21	6	.	.	PUNCT
chd-110	22	1	doi:10.9777	doi:10.9777	VERB
chd-110	22	2	/	/	SYM
chd-110	22	3	chd.2019.1005	chd.2019.1005	NUM
chd-110	22	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-110	22	5	e2	e2	PROPN
chd-110	22	6	cancer	cancer	NOUN
chd-110	22	7	health	health	NOUN
chd-110	22	8	disparities	disparity	NOUN
chd-110	22	9	research	research	NOUN
chd-110	22	10	introduction	introduction	NOUN
chd-110	22	11	in	in	ADP
chd-110	22	12	2012	2012	NUM
chd-110	22	13	,	,	PUNCT
chd-110	22	14	an	an	DET
chd-110	22	15	estimated	estimate	VERB
chd-110	22	16	14.1	14.1	NUM
chd-110	22	17	million	million	NUM
chd-110	22	18	new	new	ADJ
chd-110	22	19	cases	case	NOUN
chd-110	22	20	of	of	ADP
chd-110	22	21	cancer	cancer	NOUN
chd-110	22	22	were	be	AUX
chd-110	22	23	diagnosed	diagnose	VERB
chd-110	22	24	worldwide	worldwide	ADV
chd-110	22	25	.	.	PUNCT
chd-110	23	1	prostate	prostate	NOUN
chd-110	23	2	cancer	cancer	NOUN
chd-110	23	3	was	be	AUX
chd-110	23	4	the	the	DET
chd-110	23	5	second	second	ADJ
chd-110	23	6	most	most	ADV
chd-110	23	7	prevalent	prevalent	ADJ
chd-110	23	8	malignancy	malignancy	NOUN
chd-110	23	9	in	in	ADP
chd-110	23	10	men	man	NOUN
chd-110	23	11	after	after	ADP
chd-110	23	12	lung	lung	NOUN
chd-110	23	13	cancer	cancer	NOUN
chd-110	23	14	worldwide	worldwide	ADV
chd-110	23	15	.	.	PUNCT
chd-110	24	1	it	it	PRON
chd-110	24	2	is	be	AUX
chd-110	24	3	the	the	DET
chd-110	24	4	fifth	fifth	ADJ
chd-110	24	5	most	most	ADV
chd-110	24	6	common	common	ADJ
chd-110	24	7	cause	cause	NOUN
chd-110	24	8	of	of	ADP
chd-110	24	9	cancer	cancer	NOUN
chd-110	24	10	deaths	death	NOUN
chd-110	24	11	(	(	PUNCT
chd-110	24	12	ferlay	ferlay	NOUN
chd-110	24	13	et	et	PROPN
chd-110	24	14	al	al	PROPN
chd-110	24	15	.	.	PROPN
chd-110	24	16	,	,	PUNCT
chd-110	24	17	2015	2015	NUM
chd-110	24	18	)	)	PUNCT
chd-110	24	19	.	.	PUNCT
chd-110	25	1	in	in	ADP
chd-110	25	2	nigeria	nigeria	PROPN
chd-110	25	3	,	,	PUNCT
chd-110	25	4	it	it	PRON
chd-110	25	5	is	be	AUX
chd-110	25	6	the	the	DET
chd-110	25	7	commonest	commonest	NOUN
chd-110	25	8	malignancy	malignancy	NOUN
chd-110	25	9	in	in	ADP
chd-110	25	10	men	man	NOUN
chd-110	25	11	and	and	CCONJ
chd-110	25	12	its	its	PRON
chd-110	25	13	incidence	incidence	NOUN
chd-110	25	14	continues	continue	VERB
chd-110	25	15	to	to	PART
chd-110	25	16	rise	rise	VERB
chd-110	25	17	(	(	PUNCT
chd-110	25	18	elima	elima	NOUN
chd-110	25	19	et	et	PROPN
chd-110	25	20	al	al	PROPN
chd-110	25	21	.	.	PROPN
chd-110	25	22	,	,	PUNCT
chd-110	25	23	2012	2012	NUM
chd-110	25	24	;	;	PUNCT
chd-110	26	1	adeloye	adeloye	PROPN
chd-110	26	2	et	et	PROPN
chd-110	26	3	al	al	PROPN
chd-110	26	4	.	.	PROPN
chd-110	26	5	,	,	PUNCT
chd-110	26	6	2016	2016	NUM
chd-110	26	7	)	)	PUNCT
chd-110	26	8	.	.	PUNCT
chd-110	27	1	globally	globally	ADV
chd-110	27	2	,	,	PUNCT
chd-110	27	3	several	several	ADJ
chd-110	27	4	disparities	disparity	NOUN
chd-110	27	5	have	have	AUX
chd-110	27	6	been	be	AUX
chd-110	27	7	documented	document	VERB
chd-110	27	8	between	between	ADP
chd-110	27	9	caucasian	caucasian	ADJ
chd-110	27	10	men	man	NOUN
chd-110	27	11	and	and	CCONJ
chd-110	27	12	men	man	NOUN
chd-110	27	13	of	of	ADP
chd-110	27	14	african	african	ADJ
chd-110	27	15	descent	descent	NOUN
chd-110	27	16	.	.	PUNCT
chd-110	28	1	these	these	PRON
chd-110	28	2	include	include	VERB
chd-110	28	3	an	an	DET
chd-110	28	4	increased	increase	VERB
chd-110	28	5	risk	risk	NOUN
chd-110	28	6	of	of	ADP
chd-110	28	7	developing	develop	VERB
chd-110	28	8	prostate	prostate	NOUN
chd-110	28	9	cancer	cancer	NOUN
chd-110	28	10	in	in	ADP
chd-110	28	11	black	black	ADJ
chd-110	28	12	men	man	NOUN
chd-110	28	13	,	,	PUNCT
chd-110	28	14	younger	young	ADJ
chd-110	28	15	age	age	NOUN
chd-110	28	16	of	of	ADP
chd-110	28	17	incidence	incidence	NOUN
chd-110	28	18	in	in	ADP
chd-110	28	19	black	black	ADJ
chd-110	28	20	men	man	NOUN
chd-110	28	21	,	,	PUNCT
chd-110	28	22	and	and	CCONJ
chd-110	28	23	genetic	genetic	ADJ
chd-110	28	24	differences	difference	NOUN
chd-110	28	25	.	.	PUNCT
chd-110	29	1	these	these	DET
chd-110	29	2	factors	factor	NOUN
chd-110	29	3	might	might	AUX
chd-110	29	4	have	have	VERB
chd-110	29	5	an	an	DET
chd-110	29	6	impact	impact	NOUN
chd-110	29	7	on	on	ADP
chd-110	29	8	survival	survival	NOUN
chd-110	29	9	outcomes	outcome	NOUN
chd-110	29	10	(	(	PUNCT
chd-110	29	11	odedina	odedina	PROPN
chd-110	29	12	et	et	PROPN
chd-110	29	13	al	al	PROPN
chd-110	29	14	.	.	PROPN
chd-110	29	15	,	,	PUNCT
chd-110	29	16	2009	2009	NUM
chd-110	29	17	;	;	PUNCT
chd-110	29	18	brawley	brawley	PROPN
chd-110	29	19	,	,	PUNCT
chd-110	29	20	2012	2012	NUM
chd-110	29	21	)	)	PUNCT
chd-110	29	22	.	.	PUNCT
chd-110	30	1	prostate	prostate	NOUN
chd-110	30	2	cancer	cancer	NOUN
chd-110	30	3	management	management	NOUN
chd-110	30	4	in	in	ADP
chd-110	30	5	african	african	ADJ
chd-110	30	6	men	man	NOUN
chd-110	30	7	is	be	AUX
chd-110	30	8	quite	quite	ADV
chd-110	30	9	challenging	challenging	ADJ
chd-110	30	10	as	as	SCONJ
chd-110	30	11	most	most	ADJ
chd-110	30	12	patients	patient	NOUN
chd-110	30	13	present	present	ADJ
chd-110	30	14	with	with	ADP
chd-110	30	15	metastatic	metastatic	ADJ
chd-110	30	16	disease	disease	NOUN
chd-110	30	17	(	(	PUNCT
chd-110	30	18	shenoy	shenoy	NOUN
chd-110	30	19	et	et	PROPN
chd-110	30	20	al	al	PROPN
chd-110	30	21	.	.	PROPN
chd-110	30	22	2016	2016	NUM
chd-110	30	23	)	)	PUNCT
chd-110	30	24	.	.	PUNCT
chd-110	31	1	evidence	evidence	NOUN
chd-110	31	2	-	-	PUNCT
chd-110	31	3	based	base	VERB
chd-110	31	4	medicine	medicine	NOUN
chd-110	31	5	is	be	AUX
chd-110	31	6	a	a	DET
chd-110	31	7	crucial	crucial	ADJ
chd-110	31	8	tool	tool	NOUN
chd-110	31	9	in	in	ADP
chd-110	31	10	making	make	VERB
chd-110	31	11	clinical	clinical	ADJ
chd-110	31	12	decisions	decision	NOUN
chd-110	31	13	and	and	CCONJ
chd-110	31	14	developing	develop	VERB
chd-110	31	15	guidelines	guideline	NOUN
chd-110	31	16	for	for	ADP
chd-110	31	17	management	management	NOUN
chd-110	31	18	.	.	PUNCT
chd-110	32	1	(	(	PUNCT
chd-110	32	2	burns	burn	NOUN
chd-110	32	3	,	,	PUNCT
chd-110	32	4	rohrich	rohrich	NOUN
chd-110	32	5	,	,	PUNCT
chd-110	32	6	and	and	CCONJ
chd-110	32	7	chung	chung	PROPN
chd-110	32	8	,	,	PUNCT
chd-110	32	9	2011	2011	NUM
chd-110	32	10	)	)	PUNCT
chd-110	32	11	most	most	ADJ
chd-110	32	12	screening	screening	NOUN
chd-110	32	13	and	and	CCONJ
chd-110	32	14	treatment	treatment	NOUN
chd-110	32	15	guidelines	guideline	NOUN
chd-110	32	16	used	use	VERB
chd-110	32	17	in	in	ADP
chd-110	32	18	different	different	ADJ
chd-110	32	19	parts	part	NOUN
chd-110	32	20	of	of	ADP
chd-110	32	21	the	the	DET
chd-110	32	22	world	world	NOUN
chd-110	32	23	for	for	ADP
chd-110	32	24	managing	manage	VERB
chd-110	32	25	prostate	prostate	NOUN
chd-110	32	26	cancer	cancer	NOUN
chd-110	32	27	are	be	AUX
chd-110	32	28	formulated	formulate	VERB
chd-110	32	29	from	from	ADP
chd-110	32	30	evidence	evidence	NOUN
chd-110	32	31	-	-	PUNCT
chd-110	32	32	based	base	VERB
chd-110	32	33	results	result	NOUN
chd-110	32	34	obtained	obtain	VERB
chd-110	32	35	from	from	ADP
chd-110	32	36	mostly	mostly	ADV
chd-110	32	37	clinical	clinical	ADJ
chd-110	32	38	trials	trial	NOUN
chd-110	32	39	and	and	CCONJ
chd-110	32	40	metanalyses	metanalyse	NOUN
chd-110	32	41	on	on	ADP
chd-110	32	42	studies	study	NOUN
chd-110	32	43	conducted	conduct	VERB
chd-110	32	44	in	in	ADP
chd-110	32	45	those	those	DET
chd-110	32	46	countries	country	NOUN
chd-110	32	47	.	.	PUNCT
chd-110	33	1	the	the	DET
chd-110	33	2	national	national	PROPN
chd-110	33	3	institute	institute	PROPN
chd-110	33	4	for	for	ADP
chd-110	33	5	health	health	NOUN
chd-110	33	6	and	and	CCONJ
chd-110	33	7	care	care	PROPN
chd-110	33	8	excellence	excellence	PROPN
chd-110	33	9	(	(	PUNCT
chd-110	33	10	nice	nice	ADJ
chd-110	33	11	)	)	PUNCT
chd-110	33	12	guidelines	guideline	NOUN
chd-110	33	13	for	for	ADP
chd-110	33	14	treatment	treatment	NOUN
chd-110	33	15	is	be	AUX
chd-110	33	16	predominantly	predominantly	ADV
chd-110	33	17	based	base	VERB
chd-110	33	18	on	on	ADP
chd-110	33	19	research	research	NOUN
chd-110	33	20	carried	carry	VERB
chd-110	33	21	out	out	ADP
chd-110	33	22	in	in	ADP
chd-110	33	23	the	the	DET
chd-110	33	24	united	united	ADJ
chd-110	33	25	kingdom	kingdom	PROPN
chd-110	33	26	(	(	PUNCT
chd-110	33	27	uk	uk	PROPN
chd-110	33	28	)	)	PUNCT
chd-110	33	29	.	.	PUNCT
chd-110	34	1	a	a	DET
chd-110	34	2	similar	similar	ADJ
chd-110	34	3	situation	situation	NOUN
chd-110	34	4	pertains	pertain	NOUN
chd-110	34	5	regarding	regard	VERB
chd-110	34	6	the	the	DET
chd-110	34	7	national	national	ADJ
chd-110	34	8	comprehensive	comprehensive	ADJ
chd-110	34	9	cancer	cancer	NOUN
chd-110	34	10	network	network	NOUN
chd-110	34	11	(	(	PUNCT
chd-110	34	12	nccn	nccn	NOUN
chd-110	34	13	)	)	PUNCT
chd-110	34	14	guidelines	guideline	NOUN
chd-110	34	15	in	in	ADP
chd-110	34	16	the	the	DET
chd-110	34	17	united	united	PROPN
chd-110	34	18	states	states	PROPN
chd-110	34	19	of	of	ADP
chd-110	34	20	america	america	PROPN
chd-110	34	21	(	(	PUNCT
chd-110	34	22	usa	usa	PROPN
chd-110	34	23	)	)	PUNCT
chd-110	34	24	.	.	PUNCT
chd-110	35	1	evidence	evidence	NOUN
chd-110	35	2	based	base	VERB
chd-110	35	3	medicine	medicine	NOUN
chd-110	35	4	is	be	AUX
chd-110	35	5	a	a	DET
chd-110	35	6	concept	concept	NOUN
chd-110	35	7	developed	develop	VERB
chd-110	35	8	in	in	ADP
chd-110	35	9	the	the	DET
chd-110	35	10	early	early	ADJ
chd-110	35	11	80s	80	NOUN
chd-110	35	12	,	,	PUNCT
chd-110	35	13	then	then	ADV
chd-110	35	14	further	far	ADV
chd-110	35	15	described	describe	VERB
chd-110	35	16	and	and	CCONJ
chd-110	35	17	modified	modify	VERB
chd-110	35	18	by	by	ADP
chd-110	35	19	sackett	sackett	PROPN
chd-110	35	20	in	in	ADP
chd-110	35	21	1989	1989	NUM
chd-110	35	22	(	(	PUNCT
chd-110	35	23	sackett	sackett	PROPN
chd-110	35	24	et	et	PROPN
chd-110	35	25	al	al	PROPN
chd-110	35	26	.	.	PROPN
chd-110	35	27	,	,	PUNCT
chd-110	35	28	1996	1996	NUM
chd-110	35	29	)	)	PUNCT
chd-110	35	30	.	.	PUNCT
chd-110	36	1	it	it	PRON
chd-110	36	2	groups	group	VERB
chd-110	36	3	different	different	ADJ
chd-110	36	4	studies	study	NOUN
chd-110	36	5	based	base	VERB
chd-110	36	6	on	on	ADP
chd-110	36	7	their	their	PRON
chd-110	36	8	levels	level	NOUN
chd-110	36	9	of	of	ADP
chd-110	36	10	evidence	evidence	NOUN
chd-110	36	11	from	from	ADP
chd-110	36	12	one	one	NUM
chd-110	36	13	to	to	ADP
chd-110	36	14	five	five	NUM
chd-110	36	15	.	.	PUNCT
chd-110	37	1	randomized	randomize	VERB
chd-110	37	2	controlled	control	VERB
chd-110	37	3	trials	trial	NOUN
chd-110	37	4	(	(	PUNCT
chd-110	37	5	rct	rct	PROPN
chd-110	37	6	)	)	PUNCT
chd-110	37	7	and	and	CCONJ
chd-110	37	8	metanalyses	metanalyse	NOUN
chd-110	37	9	are	be	AUX
chd-110	37	10	placed	place	VERB
chd-110	37	11	at	at	ADP
chd-110	37	12	the	the	DET
chd-110	37	13	highest	high	ADJ
chd-110	37	14	level	level	NOUN
chd-110	37	15	of	of	ADP
chd-110	37	16	evidence	evidence	NOUN
chd-110	37	17	,	,	PUNCT
chd-110	37	18	whilst	whilst	SCONJ
chd-110	37	19	,	,	PUNCT
chd-110	37	20	case	case	NOUN
chd-110	37	21	series	series	NOUN
chd-110	37	22	,	,	PUNCT
chd-110	37	23	case	case	NOUN
chd-110	37	24	studies	study	NOUN
chd-110	37	25	and	and	CCONJ
chd-110	37	26	expert	expert	NOUN
chd-110	37	27	opinions	opinion	NOUN
chd-110	37	28	are	be	AUX
chd-110	37	29	at	at	ADP
chd-110	37	30	the	the	DET
chd-110	37	31	lowest	low	ADJ
chd-110	37	32	level	level	NOUN
chd-110	37	33	.	.	PUNCT
chd-110	38	1	rcts	rct	NOUN
chd-110	38	2	are	be	AUX
chd-110	38	3	structured	structure	VERB
chd-110	38	4	to	to	PART
chd-110	38	5	be	be	AUX
chd-110	38	6	unbiased	unbiased	ADJ
chd-110	38	7	;	;	PUNCT
chd-110	38	8	subjects	subject	NOUN
chd-110	38	9	are	be	AUX
chd-110	38	10	allocated	allocate	VERB
chd-110	38	11	randomly	randomly	ADV
chd-110	38	12	to	to	ADP
chd-110	38	13	two	two	NUM
chd-110	38	14	or	or	CCONJ
chd-110	38	15	more	more	ADJ
chd-110	38	16	treatment	treatment	NOUN
chd-110	38	17	groups	group	NOUN
chd-110	38	18	whilst	whilst	SCONJ
chd-110	38	19	case	case	NOUN
chd-110	38	20	series	series	NOUN
chd-110	38	21	or	or	CCONJ
chd-110	38	22	expert	expert	ADJ
chd-110	38	23	opinion	opinion	NOUN
chd-110	38	24	are	be	AUX
chd-110	38	25	associated	associate	VERB
chd-110	38	26	with	with	ADP
chd-110	38	27	bias	bias	NOUN
chd-110	38	28	and	and	CCONJ
chd-110	38	29	based	base	VERB
chd-110	38	30	on	on	ADP
chd-110	38	31	writer	writer	NOUN
chd-110	38	32	’s	’s	PART
chd-110	38	33	experience	experience	NOUN
chd-110	38	34	or	or	CCONJ
chd-110	38	35	opinions	opinion	NOUN
chd-110	38	36	and	and	CCONJ
chd-110	38	37	there	there	PRON
chd-110	38	38	is	be	VERB
chd-110	38	39	often	often	ADV
chd-110	38	40	no	no	DET
chd-110	38	41	control	control	NOUN
chd-110	38	42	of	of	ADP
chd-110	38	43	confounding	confound	VERB
chd-110	38	44	factors	factor	NOUN
chd-110	38	45	.	.	PUNCT
chd-110	39	1	the	the	DET
chd-110	39	2	centre	centre	NOUN
chd-110	39	3	for	for	ADP
chd-110	39	4	evidence	evidence	NOUN
chd-110	39	5	-	-	PUNCT
chd-110	39	6	based	base	VERB
chd-110	39	7	medicine	medicine	NOUN
chd-110	39	8	in	in	ADP
chd-110	39	9	oxford	oxford	PROPN
chd-110	39	10	developed	develop	VERB
chd-110	39	11	an	an	DET
chd-110	39	12	adaptable	adaptable	ADJ
chd-110	39	13	tool	tool	NOUN
chd-110	39	14	to	to	PART
chd-110	39	15	assess	assess	VERB
chd-110	39	16	the	the	DET
chd-110	39	17	levels	level	NOUN
chd-110	39	18	of	of	ADP
chd-110	39	19	evidence	evidence	NOUN
chd-110	39	20	in	in	ADP
chd-110	39	21	2011	2011	NUM
chd-110	39	22	(	(	PUNCT
chd-110	39	23	table	table	NOUN
chd-110	39	24	1	1	NUM
chd-110	39	25	)	)	PUNCT
chd-110	39	26	.	.	PUNCT
chd-110	40	1	the	the	DET
chd-110	40	2	tool	tool	NOUN
chd-110	40	3	is	be	AUX
chd-110	40	4	a	a	DET
chd-110	40	5	hierarchical	hierarchical	ADJ
chd-110	40	6	system	system	NOUN
chd-110	40	7	of	of	ADP
chd-110	40	8	classifying	classify	VERB
chd-110	40	9	based	base	VERB
chd-110	40	10	on	on	ADP
chd-110	40	11	evidence	evidence	NOUN
chd-110	40	12	and	and	CCONJ
chd-110	40	13	designed	design	VERB
chd-110	40	14	for	for	ADP
chd-110	40	15	use	use	NOUN
chd-110	40	16	by	by	ADP
chd-110	40	17	researchers	researcher	NOUN
chd-110	40	18	.	.	PUNCT
chd-110	41	1	table	table	NOUN
chd-110	41	2	1	1	NUM
chd-110	41	3	:	:	PUNCT
chd-110	41	4	the	the	DET
chd-110	41	5	centre	centre	NOUN
chd-110	41	6	for	for	ADP
chd-110	41	7	evidence	evidence	NOUN
chd-110	41	8	-	-	PUNCT
chd-110	41	9	based	base	VERB
chd-110	41	10	medicine	medicine	NOUN
chd-110	41	11	in	in	ADP
chd-110	41	12	oxford	oxford	PROPN
chd-110	41	13	published	publish	VERB
chd-110	41	14	the	the	DET
chd-110	41	15	levels	level	NOUN
chd-110	41	16	of	of	ADP
chd-110	41	17	evidence	evidence	NOUN
chd-110	41	18	in	in	ADP
chd-110	41	19	2009	2009	NUM
chd-110	41	20	,	,	PUNCT
chd-110	41	21	and	and	CCONJ
chd-110	41	22	modified	modify	VERB
chd-110	41	23	in	in	ADP
chd-110	41	24	2011(ocebm	2011(ocebm	NUM
chd-110	41	25	levels	level	NOUN
chd-110	41	26	of	of	ADP
chd-110	41	27	evidence	evidence	NOUN
chd-110	41	28	working	working	NOUN
chd-110	41	29	group	group	NOUN
chd-110	41	30	et	et	PROPN
chd-110	41	31	al	al	PROPN
chd-110	41	32	.	.	PROPN
chd-110	41	33	2011	2011	NUM
chd-110	41	34	)	)	PUNCT
chd-110	41	35	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-110	41	36	e3	e3	NOUN
chd-110	41	37	cancer	cancer	NOUN
chd-110	41	38	health	health	NOUN
chd-110	41	39	disparities	disparity	NOUN
chd-110	41	40	research	research	VERB
chd-110	41	41	in	in	ADP
chd-110	41	42	nigeria	nigeria	PROPN
chd-110	41	43	,	,	PUNCT
chd-110	41	44	prostate	prostate	NOUN
chd-110	41	45	cancer	cancer	NOUN
chd-110	41	46	prevention	prevention	NOUN
chd-110	41	47	,	,	PUNCT
chd-110	41	48	screening	screening	NOUN
chd-110	41	49	,	,	PUNCT
chd-110	41	50	and	and	CCONJ
chd-110	41	51	clinical	clinical	ADJ
chd-110	41	52	treatment	treatment	NOUN
chd-110	41	53	modalities	modality	NOUN
chd-110	41	54	should	should	AUX
chd-110	41	55	be	be	AUX
chd-110	41	56	based	base	VERB
chd-110	41	57	on	on	ADP
chd-110	41	58	evidence	evidence	NOUN
chd-110	41	59	-	-	PUNCT
chd-110	41	60	based	base	VERB
chd-110	41	61	research	research	NOUN
chd-110	41	62	done	do	VERB
chd-110	41	63	or	or	CCONJ
chd-110	41	64	validated	validate	VERB
chd-110	41	65	in	in	ADP
chd-110	41	66	nigerian	nigerian	ADJ
chd-110	41	67	patients	patient	NOUN
chd-110	41	68	,	,	PUNCT
chd-110	41	69	in	in	ADP
chd-110	41	70	the	the	DET
chd-110	41	71	expectation	expectation	NOUN
chd-110	41	72	that	that	SCONJ
chd-110	41	73	this	this	PRON
chd-110	41	74	would	would	AUX
chd-110	41	75	lead	lead	VERB
chd-110	41	76	to	to	ADP
chd-110	41	77	improved	improve	VERB
chd-110	41	78	treatment	treatment	NOUN
chd-110	41	79	outcomes	outcome	NOUN
chd-110	41	80	and	and	CCONJ
chd-110	41	81	therefore	therefore	ADV
chd-110	41	82	survival	survival	NOUN
chd-110	41	83	.	.	PUNCT
chd-110	42	1	however	however	ADV
chd-110	42	2	,	,	PUNCT
chd-110	42	3	there	there	PRON
chd-110	42	4	are	be	VERB
chd-110	42	5	no	no	DET
chd-110	42	6	publications	publication	NOUN
chd-110	42	7	exploring	explore	VERB
chd-110	42	8	the	the	DET
chd-110	42	9	levels	level	NOUN
chd-110	42	10	of	of	ADP
chd-110	42	11	evidence	evidence	NOUN
chd-110	42	12	in	in	ADP
chd-110	42	13	prostate	prostate	NOUN
chd-110	42	14	cancer	cancer	NOUN
chd-110	42	15	research	research	NOUN
chd-110	42	16	in	in	ADP
chd-110	42	17	nigeria	nigeria	PROPN
chd-110	42	18	.	.	PUNCT
chd-110	43	1	this	this	DET
chd-110	43	2	review	review	NOUN
chd-110	43	3	was	be	AUX
chd-110	43	4	done	do	VERB
chd-110	43	5	to	to	PART
chd-110	43	6	explore	explore	VERB
chd-110	43	7	levels	level	NOUN
chd-110	43	8	of	of	ADP
chd-110	43	9	evidence	evidence	NOUN
chd-110	43	10	on	on	ADP
chd-110	43	11	prostate	prostate	NOUN
chd-110	43	12	cancer	cancer	NOUN
chd-110	43	13	in	in	ADP
chd-110	43	14	nigeria	nigeria	PROPN
chd-110	43	15	.	.	PUNCT
chd-110	44	1	methods	method	NOUN
chd-110	44	2	we	we	PRON
chd-110	44	3	followed	follow	VERB
chd-110	44	4	the	the	DET
chd-110	44	5	preferred	preferred	ADJ
chd-110	44	6	reporting	reporting	NOUN
chd-110	44	7	for	for	ADP
chd-110	44	8	systematic	systematic	ADJ
chd-110	44	9	reviews	review	NOUN
chd-110	44	10	and	and	CCONJ
chd-110	44	11	meta	meta	NOUN
chd-110	44	12	-	-	PUNCT
chd-110	44	13	analyses	analysis	NOUN
chd-110	44	14	(	(	PUNCT
chd-110	44	15	prisma	prisma	NOUN
chd-110	44	16	)	)	PUNCT
chd-110	44	17	statement	statement	NOUN
chd-110	44	18	for	for	ADP
chd-110	44	19	the	the	DET
chd-110	44	20	conduct	conduct	NOUN
chd-110	44	21	of	of	ADP
chd-110	44	22	our	our	PRON
chd-110	44	23	systematic	systematic	ADJ
chd-110	44	24	review	review	NOUN
chd-110	44	25	(	(	PUNCT
chd-110	44	26	except	except	SCONJ
chd-110	44	27	that	that	SCONJ
chd-110	44	28	we	we	PRON
chd-110	44	29	did	do	AUX
chd-110	44	30	not	not	PART
chd-110	44	31	consider	consider	VERB
chd-110	44	32	metanalyses	metanalyse	NOUN
chd-110	44	33	)	)	PUNCT
chd-110	44	34	.	.	PUNCT
chd-110	45	1	figure	figure	VERB
chd-110	45	2	1	1	NUM
chd-110	45	3	:	:	PUNCT
chd-110	45	4	illustrating	illustrate	VERB
chd-110	45	5	the	the	DET
chd-110	45	6	prisma	prisma	NOUN
chd-110	45	7	selection	selection	NOUN
chd-110	45	8	criteria	criterion	NOUN
chd-110	45	9	study	study	NOUN
chd-110	45	10	selection	selection	NOUN
chd-110	45	11	an	an	DET
chd-110	45	12	electronic	electronic	ADJ
chd-110	45	13	literature	literature	NOUN
chd-110	45	14	search	search	NOUN
chd-110	45	15	of	of	ADP
chd-110	45	16	all	all	DET
chd-110	45	17	research	research	NOUN
chd-110	45	18	published	publish	VERB
chd-110	45	19	on	on	ADP
chd-110	45	20	prostate	prostate	NOUN
chd-110	45	21	cancer	cancer	NOUN
chd-110	45	22	from	from	ADP
chd-110	45	23	january	january	PROPN
chd-110	45	24	1975	1975	NUM
chd-110	45	25	to	to	PART
chd-110	45	26	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-110	45	27	e4	e4	PROPN
chd-110	45	28	cancer	cancer	NOUN
chd-110	45	29	health	health	NOUN
chd-110	45	30	disparities	disparity	NOUN
chd-110	45	31	research	research	NOUN
chd-110	45	32	may	may	AUX
chd-110	45	33	2018	2018	NUM
chd-110	45	34	in	in	ADP
chd-110	45	35	nigeria	nigeria	PROPN
chd-110	45	36	was	be	AUX
chd-110	45	37	conducted	conduct	VERB
chd-110	45	38	.	.	PUNCT
chd-110	46	1	we	we	PRON
chd-110	46	2	reviewed	review	VERB
chd-110	46	3	all	all	DET
chd-110	46	4	articles	article	NOUN
chd-110	46	5	found	find	VERB
chd-110	46	6	on	on	ADP
chd-110	46	7	pubmed	pubmed	PROPN
chd-110	46	8	,	,	PUNCT
chd-110	46	9	web	web	NOUN
chd-110	46	10	of	of	ADP
chd-110	46	11	science	science	NOUN
chd-110	46	12	,	,	PUNCT
chd-110	46	13	embase	embase	NOUN
chd-110	46	14	,	,	PUNCT
chd-110	46	15	and	and	CCONJ
chd-110	46	16	google	google	PROPN
chd-110	46	17	scholar	scholar	NOUN
chd-110	46	18	search	search	NOUN
chd-110	46	19	engines	engine	NOUN
chd-110	46	20	by	by	ADP
chd-110	46	21	searching	search	VERB
chd-110	46	22	“	"	PUNCT
chd-110	46	23	prostate	prostate	NOUN
chd-110	46	24	cancer	cancer	NOUN
chd-110	46	25	in	in	ADP
chd-110	46	26	nigeria	nigeria	PROPN
chd-110	46	27	”	"	PUNCT
chd-110	46	28	.	.	PUNCT
chd-110	47	1	using	use	VERB
chd-110	47	2	the	the	DET
chd-110	47	3	prisma	prisma	NOUN
chd-110	47	4	and	and	CCONJ
chd-110	47	5	national	national	PROPN
chd-110	47	6	institute	institute	PROPN
chd-110	47	7	of	of	ADP
chd-110	47	8	health	health	PROPN
chd-110	47	9	(	(	PUNCT
chd-110	47	10	nih	nih	NOUN
chd-110	47	11	)	)	PUNCT
chd-110	47	12	guidelines	guideline	NOUN
chd-110	47	13	,	,	PUNCT
chd-110	47	14	we	we	PRON
chd-110	47	15	reviewed	review	VERB
chd-110	47	16	and	and	CCONJ
chd-110	47	17	classified	classify	VERB
chd-110	47	18	the	the	DET
chd-110	47	19	articles	article	NOUN
chd-110	47	20	based	base	VERB
chd-110	47	21	on	on	ADP
chd-110	47	22	their	their	PRON
chd-110	47	23	study	study	NOUN
chd-110	47	24	designs	design	NOUN
chd-110	47	25	into	into	ADP
chd-110	47	26	different	different	ADJ
chd-110	47	27	levels	level	NOUN
chd-110	47	28	of	of	ADP
chd-110	47	29	evidence	evidence	NOUN
chd-110	47	30	.	.	PUNCT
chd-110	48	1	we	we	PRON
chd-110	48	2	included	include	VERB
chd-110	48	3	all	all	DET
chd-110	48	4	studies	study	NOUN
chd-110	48	5	on	on	ADP
chd-110	48	6	prostate	prostate	NOUN
chd-110	48	7	cancer	cancer	NOUN
chd-110	48	8	in	in	ADP
chd-110	48	9	nigeria	nigeria	PROPN
chd-110	48	10	with	with	ADP
chd-110	48	11	either	either	CCONJ
chd-110	48	12	the	the	DET
chd-110	48	13	full	full	ADJ
chd-110	48	14	article	article	NOUN
chd-110	48	15	or	or	CCONJ
chd-110	48	16	abstract	abstract	ADJ
chd-110	48	17	having	have	VERB
chd-110	48	18	adequate	adequate	ADJ
chd-110	48	19	information	information	NOUN
chd-110	48	20	on	on	ADP
chd-110	48	21	the	the	DET
chd-110	48	22	methodology	methodology	NOUN
chd-110	48	23	of	of	ADP
chd-110	48	24	the	the	DET
chd-110	48	25	study	study	NOUN
chd-110	48	26	and	and	CCONJ
chd-110	48	27	excluded	exclude	VERB
chd-110	48	28	those	those	PRON
chd-110	48	29	with	with	ADP
chd-110	48	30	insufficient	insufficient	ADJ
chd-110	48	31	details	detail	NOUN
chd-110	48	32	.	.	PUNCT
chd-110	49	1	information	information	NOUN
chd-110	49	2	extracted	extract	VERB
chd-110	49	3	from	from	ADP
chd-110	49	4	studies	study	NOUN
chd-110	49	5	include	include	VERB
chd-110	49	6	the	the	DET
chd-110	49	7	year	year	NOUN
chd-110	49	8	of	of	ADP
chd-110	49	9	publications	publication	NOUN
chd-110	49	10	,	,	PUNCT
chd-110	49	11	study	study	NOUN
chd-110	49	12	design	design	NOUN
chd-110	49	13	,	,	PUNCT
chd-110	49	14	and	and	CCONJ
chd-110	49	15	level	level	NOUN
chd-110	49	16	of	of	ADP
chd-110	49	17	evidence	evidence	NOUN
chd-110	49	18	.	.	PUNCT
chd-110	50	1	studies	study	NOUN
chd-110	50	2	selected	select	VERB
chd-110	50	3	were	be	AUX
chd-110	50	4	grouped	group	VERB
chd-110	50	5	into	into	ADP
chd-110	50	6	five	five	NUM
chd-110	50	7	levels	level	NOUN
chd-110	50	8	of	of	ADP
chd-110	50	9	evidence	evidence	NOUN
chd-110	50	10	according	accord	VERB
chd-110	50	11	to	to	ADP
chd-110	50	12	the	the	DET
chd-110	50	13	oxford	oxford	ADJ
chd-110	50	14	centre	centre	NOUN
chd-110	50	15	for	for	ADP
chd-110	50	16	evidencebased	evidencebased	ADJ
chd-110	50	17	medicine	medicine	NOUN
chd-110	50	18	classification	classification	NOUN
chd-110	50	19	(	(	PUNCT
chd-110	50	20	ocebm	ocebm	PROPN
chd-110	50	21	levels	level	NOUN
chd-110	50	22	of	of	ADP
chd-110	50	23	evidence	evidence	NOUN
chd-110	50	24	working	working	NOUN
chd-110	50	25	group	group	NOUN
chd-110	50	26	et	et	PROPN
chd-110	50	27	al	al	PROPN
chd-110	50	28	.	.	PROPN
chd-110	50	29	2011	2011	NUM
chd-110	50	30	)	)	PUNCT
chd-110	50	31	.	.	PUNCT
chd-110	51	1	metaanalyses	metaanalyse	NOUN
chd-110	51	2	were	be	AUX
chd-110	51	3	not	not	PART
chd-110	51	4	considered	consider	VERB
chd-110	51	5	in	in	ADP
chd-110	51	6	the	the	DET
chd-110	51	7	review	review	NOUN
chd-110	51	8	due	due	ADP
chd-110	51	9	to	to	ADP
chd-110	51	10	varying	vary	VERB
chd-110	51	11	study	study	NOUN
chd-110	51	12	designs	design	NOUN
chd-110	51	13	and	and	CCONJ
chd-110	51	14	difficulty	difficulty	NOUN
chd-110	51	15	in	in	ADP
chd-110	51	16	pooling	pool	VERB
chd-110	51	17	them	they	PRON
chd-110	51	18	together	together	ADV
chd-110	51	19	.	.	PUNCT
chd-110	52	1	evidence	evidence	NOUN
chd-110	52	2	synthesis	synthesis	NOUN
chd-110	52	3	during	during	ADP
chd-110	52	4	our	our	PRON
chd-110	52	5	search	search	NOUN
chd-110	52	6	we	we	PRON
chd-110	52	7	identified	identify	VERB
chd-110	52	8	302	302	NUM
chd-110	52	9	publications	publication	NOUN
chd-110	52	10	,	,	PUNCT
chd-110	52	11	106	106	NUM
chd-110	52	12	duplicates	duplicate	NOUN
chd-110	52	13	were	be	AUX
chd-110	52	14	removed	remove	VERB
chd-110	52	15	and	and	CCONJ
chd-110	52	16	25	25	NUM
chd-110	52	17	were	be	AUX
chd-110	52	18	excluded	exclude	VERB
chd-110	52	19	based	base	VERB
chd-110	52	20	on	on	ADP
chd-110	52	21	inadequate	inadequate	ADJ
chd-110	52	22	information	information	NOUN
chd-110	52	23	on	on	ADP
chd-110	52	24	the	the	DET
chd-110	52	25	methodology	methodology	NOUN
chd-110	52	26	of	of	ADP
chd-110	52	27	the	the	DET
chd-110	52	28	study	study	NOUN
chd-110	52	29	.	.	PUNCT
chd-110	53	1	a	a	DET
chd-110	53	2	total	total	NOUN
chd-110	53	3	of	of	ADP
chd-110	53	4	171	171	NUM
chd-110	53	5	articles	article	NOUN
chd-110	53	6	were	be	AUX
chd-110	53	7	eligible	eligible	ADJ
chd-110	53	8	for	for	ADP
chd-110	53	9	this	this	DET
chd-110	53	10	review	review	NOUN
chd-110	53	11	.	.	PUNCT
chd-110	54	1	most	most	ADJ
chd-110	54	2	studies	study	NOUN
chd-110	54	3	published	publish	VERB
chd-110	54	4	were	be	AUX
chd-110	54	5	cross	cross	ADJ
chd-110	54	6	sectional	sectional	ADJ
chd-110	54	7	studies	study	NOUN
chd-110	54	8	(	(	PUNCT
chd-110	54	9	56	56	NUM
chd-110	54	10	%	%	NOUN
chd-110	54	11	)	)	PUNCT
chd-110	54	12	,	,	PUNCT
chd-110	54	13	followed	follow	VERB
chd-110	54	14	by	by	ADP
chd-110	54	15	cohort	cohort	NOUN
chd-110	54	16	studies	study	NOUN
chd-110	54	17	(	(	PUNCT
chd-110	54	18	15	15	NUM
chd-110	54	19	%	%	NOUN
chd-110	54	20	)	)	PUNCT
chd-110	54	21	,	,	PUNCT
chd-110	54	22	laboratory	laboratory	NOUN
chd-110	54	23	studies(13	studies(13	NOUN
chd-110	54	24	%	%	NOUN
chd-110	54	25	)	)	PUNCT
chd-110	54	26	,	,	PUNCT
chd-110	54	27	case	case	NOUN
chd-110	54	28	reports	report	NOUN
chd-110	54	29	(	(	PUNCT
chd-110	54	30	7	7	NUM
chd-110	54	31	%	%	NOUN
chd-110	54	32	)	)	PUNCT
chd-110	54	33	,	,	PUNCT
chd-110	54	34	expert	expert	ADJ
chd-110	54	35	opinion	opinion	NOUN
chd-110	54	36	(	(	PUNCT
chd-110	54	37	3	3	NUM
chd-110	54	38	%	%	NOUN
chd-110	54	39	)	)	PUNCT
chd-110	54	40	,	,	PUNCT
chd-110	54	41	systematic	systematic	ADJ
chd-110	54	42	reviews	review	NOUN
chd-110	54	43	(	(	PUNCT
chd-110	54	44	2	2	NUM
chd-110	54	45	%	%	NOUN
chd-110	54	46	)	)	PUNCT
chd-110	54	47	and	and	CCONJ
chd-110	54	48	meta	meta	ADJ
chd-110	54	49	-	-	PUNCT
chd-110	54	50	analysis	analysis	NOUN
chd-110	54	51	(	(	PUNCT
chd-110	54	52	1	1	NUM
chd-110	54	53	%	%	NOUN
chd-110	54	54	)	)	PUNCT
chd-110	54	55	.	.	PUNCT
chd-110	55	1	there	there	PRON
chd-110	55	2	were	be	VERB
chd-110	55	3	no	no	DET
chd-110	55	4	clinical	clinical	ADJ
chd-110	55	5	trials	trial	NOUN
chd-110	55	6	on	on	ADP
chd-110	55	7	prostate	prostate	NOUN
chd-110	55	8	cancer	cancer	NOUN
chd-110	55	9	in	in	ADP
chd-110	55	10	nigeria	nigeria	PROPN
chd-110	55	11	seen	see	VERB
chd-110	55	12	or	or	CCONJ
chd-110	55	13	registered	register	VERB
chd-110	55	14	on	on	ADP
chd-110	55	15	clinicaltrials.gov	clinicaltrials.gov	NOUN
chd-110	55	16	or	or	CCONJ
chd-110	55	17	other	other	ADJ
chd-110	55	18	clinical	clinical	ADJ
chd-110	55	19	trials	trial	NOUN
chd-110	55	20	registries	registry	NOUN
chd-110	55	21	(	(	PUNCT
chd-110	55	22	figure	figure	NOUN
chd-110	55	23	2	2	NUM
chd-110	55	24	)	)	PUNCT
chd-110	55	25	.	.	PUNCT
chd-110	56	1	figure	figure	VERB
chd-110	56	2	2	2	NUM
chd-110	56	3	:	:	PUNCT
chd-110	56	4	types	type	NOUN
chd-110	56	5	of	of	ADP
chd-110	56	6	study	study	NOUN
chd-110	56	7	designs	design	NOUN
chd-110	56	8	on	on	ADP
chd-110	56	9	prostate	prostate	NOUN
chd-110	56	10	cancer	cancer	NOUN
chd-110	56	11	in	in	ADP
chd-110	56	12	nigeria	nigeria	PROPN
chd-110	56	13	based	base	VERB
chd-110	56	14	on	on	ADP
chd-110	56	15	levels	level	NOUN
chd-110	56	16	of	of	ADP
chd-110	56	17	evidence	evidence	NOUN
chd-110	56	18	,	,	PUNCT
chd-110	56	19	most	most	ADJ
chd-110	56	20	studies	study	NOUN
chd-110	56	21	(	(	PUNCT
chd-110	56	22	66	66	NUM
chd-110	56	23	%	%	NOUN
chd-110	56	24	)	)	PUNCT
chd-110	56	25	,	,	PUNCT
chd-110	56	26	were	be	AUX
chd-110	56	27	at	at	ADP
chd-110	56	28	level	level	NOUN
chd-110	56	29	4a	4a	NUM
chd-110	56	30	of	of	ADP
chd-110	56	31	evidence	evidence	NOUN
chd-110	56	32	(	(	PUNCT
chd-110	56	33	figure	figure	NOUN
chd-110	56	34	3	3	NUM
chd-110	56	35	)	)	PUNCT
chd-110	56	36	.	.	PUNCT
chd-110	57	1	these	these	PRON
chd-110	57	2	include	include	VERB
chd-110	57	3	case	case	NOUN
chd-110	57	4	reports	report	NOUN
chd-110	57	5	,	,	PUNCT
chd-110	57	6	case	case	NOUN
chd-110	57	7	series	series	NOUN
chd-110	57	8	,	,	PUNCT
chd-110	57	9	and	and	CCONJ
chd-110	57	10	cross	cross	ADJ
chd-110	57	11	-	-	ADJ
chd-110	57	12	sectional	sectional	ADJ
chd-110	57	13	studies	study	NOUN
chd-110	57	14	.	.	PUNCT
chd-110	58	1	seventeen	seventeen	NUM
chd-110	58	2	percent	percent	NOUN
chd-110	58	3	of	of	ADP
chd-110	58	4	studies	study	NOUN
chd-110	58	5	were	be	AUX
chd-110	58	6	at	at	ADP
chd-110	58	7	the	the	DET
chd-110	58	8	level	level	NOUN
chd-110	58	9	5a	5a	NUM
chd-110	58	10	evidence	evidence	NOUN
chd-110	58	11	levels	level	NOUN
chd-110	58	12	,	,	PUNCT
chd-110	58	13	including	include	VERB
chd-110	58	14	laboratory	laboratory	NOUN
chd-110	58	15	studies	study	NOUN
chd-110	58	16	and	and	CCONJ
chd-110	58	17	expert	expert	NOUN
chd-110	58	18	opinion	opinion	NOUN
chd-110	58	19	.	.	PUNCT
chd-110	59	1	nine	nine	NUM
chd-110	59	2	percent	percent	NOUN
chd-110	59	3	of	of	ADP
chd-110	59	4	the	the	DET
chd-110	59	5	studies	study	NOUN
chd-110	59	6	were	be	AUX
chd-110	59	7	at	at	ADP
chd-110	59	8	level	level	NOUN
chd-110	59	9	2b	2b	NUM
chd-110	59	10	of	of	ADP
chd-110	59	11	evidence	evidence	NOUN
chd-110	59	12	,	,	PUNCT
chd-110	59	13	which	which	PRON
chd-110	59	14	included	include	VERB
chd-110	59	15	cohort	cohort	NOUN
chd-110	59	16	studies	study	NOUN
chd-110	59	17	,	,	PUNCT
chd-110	59	18	5	5	NUM
chd-110	59	19	%	%	NOUN
chd-110	59	20	at	at	ADP
chd-110	59	21	level	level	NOUN
chd-110	59	22	3b	3b	NOUN
chd-110	59	23	of	of	ADP
chd-110	59	24	evidence	evidence	NOUN
chd-110	59	25	including	include	VERB
chd-110	59	26	casecontrol	casecontrol	NOUN
chd-110	59	27	1	1	NUM
chd-110	59	28	3	3	NUM
chd-110	59	29	0	0	NUM
chd-110	59	30	0	0	NUM
chd-110	59	31	25	25	NUM
chd-110	59	32	8	8	NUM
chd-110	59	33	95	95	NUM
chd-110	59	34	12	12	NUM
chd-110	59	35	5	5	NUM
chd-110	59	36	22	22	NUM
chd-110	59	37	meta	meta	ADJ
chd-110	59	38	-	-	PUNCT
chd-110	59	39	analysis	analysis	NOUN
chd-110	59	40	systematic	systematic	ADJ
chd-110	59	41	reviews	review	NOUN
chd-110	59	42	randomised	randomise	VERB
chd-110	59	43	clinical	clinical	ADJ
chd-110	59	44	trials	trial	NOUN
chd-110	59	45	non	non	X
chd-110	59	46	randomised	randomise	VERB
chd-110	59	47	clinical	clinical	ADJ
chd-110	59	48	trials	trial	NOUN
chd-110	59	49	cohort	cohort	NOUN
chd-110	59	50	studies	study	NOUN
chd-110	59	51	case	case	NOUN
chd-110	59	52	-	-	PUNCT
chd-110	59	53	control	control	NOUN
chd-110	59	54	studies	study	NOUN
chd-110	59	55	cross	cross	ADJ
chd-110	59	56	-	-	ADJ
chd-110	59	57	sectional	sectional	ADJ
chd-110	59	58	studies	study	NOUN
chd-110	59	59	case	case	NOUN
chd-110	59	60	reports/	reports/	NOUN
chd-110	59	61	case	case	NOUN
chd-110	59	62	series	series	PROPN
chd-110	59	63	background	background	NOUN
chd-110	59	64	information	information	NOUN
chd-110	59	65	/	/	SYM
chd-110	59	66	expert	expert	NOUN
chd-110	59	67	opinion	opinion	NOUN
chd-110	59	68	animal	animal	NOUN
chd-110	59	69	research	research	NOUN
chd-110	59	70	/	/	SYM
chd-110	59	71	lab	lab	NOUN
chd-110	59	72	studies	study	NOUN
chd-110	59	73	types	type	NOUN
chd-110	59	74	of	of	ADP
chd-110	59	75	study	study	NOUN
chd-110	59	76	designs	design	NOUN
chd-110	59	77	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-110	59	78	e5	e5	PROPN
chd-110	59	79	cancer	cancer	NOUN
chd-110	59	80	health	health	NOUN
chd-110	59	81	disparities	disparity	NOUN
chd-110	59	82	research	research	NOUN
chd-110	59	83	studies	study	NOUN
chd-110	59	84	,	,	PUNCT
chd-110	59	85	whilst	whilst	SCONJ
chd-110	59	86	levels	level	NOUN
chd-110	59	87	2c	2c	NUM
chd-110	59	88	and	and	CCONJ
chd-110	59	89	2a	2a	NUM
chd-110	59	90	constituted	constitute	VERB
chd-110	59	91	2	2	NUM
chd-110	59	92	%	%	NOUN
chd-110	59	93	and	and	CCONJ
chd-110	59	94	1	1	NUM
chd-110	59	95	%	%	NOUN
chd-110	59	96	respectively	respectively	ADV
chd-110	59	97	.	.	PUNCT
chd-110	60	1	there	there	PRON
chd-110	60	2	were	be	VERB
chd-110	60	3	no	no	DET
chd-110	60	4	studies	study	NOUN
chd-110	60	5	at	at	ADP
chd-110	60	6	level	level	NOUN
chd-110	60	7	1	1	NUM
chd-110	60	8	(	(	PUNCT
chd-110	60	9	a	a	DET
chd-110	60	10	,	,	PUNCT
chd-110	60	11	b	b	NOUN
chd-110	60	12	or	or	CCONJ
chd-110	60	13	c	c	NOUN
chd-110	60	14	)	)	PUNCT
chd-110	60	15	of	of	ADP
chd-110	60	16	evidence	evidence	NOUN
chd-110	60	17	(	(	PUNCT
chd-110	60	18	systematic	systematic	ADJ
chd-110	60	19	reviews	review	NOUN
chd-110	60	20	with	with	ADP
chd-110	60	21	homogeneity	homogeneity	NOUN
chd-110	60	22	of	of	ADP
chd-110	60	23	randomised	randomised	ADJ
chd-110	60	24	clinical	clinical	ADJ
chd-110	60	25	trials	trial	NOUN
chd-110	60	26	,	,	PUNCT
chd-110	60	27	individual	individual	NOUN
chd-110	60	28	randomised	randomise	VERB
chd-110	60	29	clinical	clinical	ADJ
chd-110	60	30	trials	trial	NOUN
chd-110	60	31	and	and	CCONJ
chd-110	60	32	all	all	DET
chd-110	60	33	or	or	CCONJ
chd-110	60	34	none	none	NOUN
chd-110	60	35	studies	study	NOUN
chd-110	60	36	)	)	PUNCT
chd-110	60	37	.	.	PUNCT
chd-110	61	1	figure	figure	VERB
chd-110	61	2	3	3	NUM
chd-110	61	3	:	:	PUNCT
chd-110	61	4	levels	level	NOUN
chd-110	61	5	of	of	ADP
chd-110	61	6	evidence	evidence	NOUN
chd-110	61	7	on	on	ADP
chd-110	61	8	prostate	prostate	NOUN
chd-110	61	9	cancer	cancer	NOUN
chd-110	61	10	research	research	NOUN
chd-110	61	11	in	in	ADP
chd-110	61	12	nigeria	nigeria	PROPN
chd-110	61	13	most	most	ADJ
chd-110	61	14	studies	study	NOUN
chd-110	61	15	were	be	AUX
chd-110	61	16	published	publish	VERB
chd-110	61	17	in	in	ADP
chd-110	61	18	2017	2017	NUM
chd-110	61	19	(	(	PUNCT
chd-110	61	20	29	29	NUM
chd-110	61	21	publications	publication	NOUN
chd-110	61	22	were	be	AUX
chd-110	61	23	identified	identify	VERB
chd-110	61	24	that	that	DET
chd-110	61	25	year	year	NOUN
chd-110	61	26	)	)	PUNCT
chd-110	61	27	,	,	PUNCT
chd-110	61	28	followed	follow	VERB
chd-110	61	29	by	by	ADP
chd-110	61	30	2012	2012	NUM
chd-110	61	31	,	,	PUNCT
chd-110	61	32	18	18	NUM
chd-110	61	33	publications	publication	NOUN
chd-110	61	34	,	,	PUNCT
chd-110	61	35	2013	2013	NUM
chd-110	61	36	,	,	PUNCT
chd-110	61	37	2014	2014	NUM
chd-110	61	38	and	and	CCONJ
chd-110	61	39	2015	2015	NUM
chd-110	61	40	had	have	VERB
chd-110	61	41	11	11	NUM
chd-110	61	42	,	,	PUNCT
chd-110	61	43	12	12	NUM
chd-110	61	44	&	&	CCONJ
chd-110	61	45	13	13	NUM
chd-110	61	46	publications	publication	NOUN
chd-110	61	47	respectively	respectively	ADV
chd-110	61	48	(	(	PUNCT
chd-110	61	49	figure	figure	NOUN
chd-110	61	50	4	4	NUM
chd-110	61	51	)	)	PUNCT
chd-110	61	52	.	.	PUNCT
chd-110	62	1	0	0	NUM
chd-110	63	1	20	20	NUM
chd-110	63	2	40	40	NUM
chd-110	63	3	60	60	NUM
chd-110	63	4	80	80	NUM
chd-110	63	5	100	100	NUM
chd-110	63	6	120	120	NUM
chd-110	63	7	1a	1a	NOUN
chd-110	63	8	1b	1b	NUM
chd-110	63	9	1c	1c	NUM
chd-110	63	10	2a	2a	NUM
chd-110	63	11	2b	2b	NUM
chd-110	63	12	2c	2c	NUM
chd-110	63	13	3a	3a	NUM
chd-110	63	14	3b	3b	NUM
chd-110	63	15	4a	4a	NOUN
chd-110	63	16	5a	5a	NUM
chd-110	63	17	levels	level	NOUN
chd-110	63	18	of	of	ADP
chd-110	63	19	evidence	evidence	NOUN
chd-110	63	20	on	on	ADP
chd-110	63	21	prostate	prostate	NOUN
chd-110	63	22	cancer	cancer	NOUN
chd-110	63	23	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-110	63	24	e6	e6	VERB
chd-110	63	25	cancer	cancer	NOUN
chd-110	63	26	health	health	NOUN
chd-110	63	27	disparities	disparity	NOUN
chd-110	63	28	research	research	NOUN
chd-110	63	29	figure	figure	NOUN
chd-110	63	30	4	4	NUM
chd-110	63	31	:	:	PUNCT
chd-110	63	32	showing	show	VERB
chd-110	63	33	number	number	NOUN
chd-110	63	34	of	of	ADP
chd-110	63	35	publications	publication	NOUN
chd-110	63	36	per	per	ADP
chd-110	63	37	year	year	NOUN
chd-110	63	38	discussion	discussion	NOUN
chd-110	63	39	this	this	DET
chd-110	63	40	study	study	NOUN
chd-110	63	41	demonstrates	demonstrate	VERB
chd-110	63	42	the	the	DET
chd-110	63	43	paucity	paucity	NOUN
chd-110	63	44	of	of	ADP
chd-110	63	45	high	high	ADJ
chd-110	63	46	level	level	NOUN
chd-110	63	47	evidence	evidence	NOUN
chd-110	63	48	research	research	NOUN
chd-110	63	49	in	in	ADP
chd-110	63	50	prostate	prostate	NOUN
chd-110	63	51	cancer	cancer	NOUN
chd-110	63	52	in	in	ADP
chd-110	63	53	nigeria	nigeria	PROPN
chd-110	63	54	.	.	PUNCT
chd-110	64	1	it	it	PRON
chd-110	64	2	showed	show	VERB
chd-110	64	3	that	that	SCONJ
chd-110	64	4	the	the	DET
chd-110	64	5	commonest	commonest	NOUN
chd-110	64	6	study	study	NOUN
chd-110	64	7	design	design	NOUN
chd-110	64	8	in	in	ADP
chd-110	64	9	prostate	prostate	NOUN
chd-110	64	10	cancer	cancer	NOUN
chd-110	64	11	research	research	NOUN
chd-110	64	12	conducted	conduct	VERB
chd-110	64	13	in	in	ADP
chd-110	64	14	nigeria	nigeria	PROPN
chd-110	64	15	is	be	AUX
chd-110	64	16	the	the	DET
chd-110	64	17	cross	cross	ADJ
chd-110	64	18	-	-	ADJ
chd-110	64	19	sectional	sectional	ADJ
chd-110	64	20	study	study	NOUN
chd-110	64	21	.	.	PUNCT
chd-110	65	1	although	although	SCONJ
chd-110	65	2	,	,	PUNCT
chd-110	65	3	this	this	DET
chd-110	65	4	design	design	NOUN
chd-110	65	5	can	can	AUX
chd-110	65	6	rapidly	rapidly	ADV
chd-110	65	7	generate	generate	VERB
chd-110	65	8	data	datum	NOUN
chd-110	65	9	on	on	ADP
chd-110	65	10	some	some	DET
chd-110	65	11	health	health	NOUN
chd-110	65	12	-	-	PUNCT
chd-110	65	13	related	relate	VERB
chd-110	65	14	events	event	NOUN
chd-110	65	15	,	,	PUNCT
chd-110	65	16	it	it	PRON
chd-110	65	17	may	may	AUX
chd-110	65	18	however	however	ADV
chd-110	65	19	be	be	AUX
chd-110	65	20	plagued	plague	VERB
chd-110	65	21	with	with	ADP
chd-110	65	22	different	different	ADJ
chd-110	65	23	types	type	NOUN
chd-110	65	24	of	of	ADP
chd-110	65	25	bias	bias	NOUN
chd-110	65	26	(	(	PUNCT
chd-110	65	27	sedgwick	sedgwick	PROPN
chd-110	65	28	2014	2014	NUM
chd-110	65	29	)	)	PUNCT
chd-110	65	30	.	.	PUNCT
chd-110	66	1	cross	cross	PROPN
chd-110	66	2	sectional	sectional	ADJ
chd-110	66	3	studies	study	NOUN
chd-110	66	4	can	can	AUX
chd-110	66	5	be	be	AUX
chd-110	66	6	used	use	VERB
chd-110	66	7	to	to	PART
chd-110	66	8	generate	generate	VERB
chd-110	66	9	a	a	DET
chd-110	66	10	hypothesis	hypothesis	NOUN
chd-110	66	11	and	and	CCONJ
chd-110	66	12	establish	establish	VERB
chd-110	66	13	an	an	DET
chd-110	66	14	association	association	NOUN
chd-110	66	15	but	but	CCONJ
chd-110	66	16	not	not	PART
chd-110	66	17	causation	causation	NOUN
chd-110	66	18	.	.	PUNCT
chd-110	67	1	most	most	ADJ
chd-110	67	2	researchers	researcher	NOUN
chd-110	67	3	in	in	ADP
chd-110	67	4	nigeria	nigeria	PROPN
chd-110	67	5	adopt	adopt	VERB
chd-110	67	6	this	this	DET
chd-110	67	7	methodology	methodology	NOUN
chd-110	67	8	because	because	SCONJ
chd-110	67	9	cross	cross	VERB
chd-110	67	10	sectional	sectional	ADJ
chd-110	67	11	studies	study	NOUN
chd-110	67	12	are	be	AUX
chd-110	67	13	relatively	relatively	ADV
chd-110	67	14	cheap	cheap	ADJ
chd-110	67	15	and	and	CCONJ
chd-110	67	16	easy	easy	ADJ
chd-110	67	17	to	to	PART
chd-110	67	18	conduct	conduct	VERB
chd-110	67	19	,	,	PUNCT
chd-110	67	20	especially	especially	ADV
chd-110	67	21	in	in	ADP
chd-110	67	22	a	a	DET
chd-110	67	23	low	low	ADJ
chd-110	67	24	-	-	PUNCT
chd-110	67	25	resource	resource	NOUN
chd-110	67	26	environment	environment	NOUN
chd-110	67	27	where	where	SCONJ
chd-110	67	28	the	the	DET
chd-110	67	29	financial	financial	ADJ
chd-110	67	30	and	and	CCONJ
chd-110	67	31	personnel	personnel	NOUN
chd-110	67	32	costs	cost	NOUN
chd-110	67	33	are	be	AUX
chd-110	67	34	lower	low	ADJ
chd-110	67	35	than	than	ADP
chd-110	67	36	that	that	PRON
chd-110	67	37	required	require	VERB
chd-110	67	38	for	for	ADP
chd-110	67	39	higher	high	ADJ
chd-110	67	40	level	level	NOUN
chd-110	67	41	and	and	CCONJ
chd-110	67	42	more	more	ADV
chd-110	67	43	informative	informative	ADJ
chd-110	67	44	studies	study	NOUN
chd-110	67	45	.	.	PUNCT
chd-110	68	1	there	there	PRON
chd-110	68	2	are	be	VERB
chd-110	68	3	very	very	ADV
chd-110	68	4	limited	limited	ADJ
chd-110	68	5	funding	funding	NOUN
chd-110	68	6	avenues	avenue	NOUN
chd-110	68	7	available	available	ADJ
chd-110	68	8	for	for	ADP
chd-110	68	9	research	research	NOUN
chd-110	68	10	in	in	ADP
chd-110	68	11	nigeria	nigeria	PROPN
chd-110	68	12	.	.	PUNCT
chd-110	69	1	studies	study	NOUN
chd-110	69	2	at	at	ADP
chd-110	69	3	higher	high	ADJ
chd-110	69	4	levels	level	NOUN
chd-110	69	5	of	of	ADP
chd-110	69	6	evidence	evidence	NOUN
chd-110	69	7	,	,	PUNCT
chd-110	69	8	like	like	ADP
chd-110	69	9	clinical	clinical	ADJ
chd-110	69	10	trials	trial	NOUN
chd-110	69	11	,	,	PUNCT
chd-110	69	12	are	be	AUX
chd-110	69	13	more	more	ADV
chd-110	69	14	rigorous	rigorous	ADJ
chd-110	69	15	,	,	PUNCT
chd-110	69	16	require	require	VERB
chd-110	69	17	higher	high	ADJ
chd-110	69	18	levels	level	NOUN
chd-110	69	19	of	of	ADP
chd-110	69	20	expertise	expertise	NOUN
chd-110	69	21	and	and	CCONJ
chd-110	69	22	are	be	AUX
chd-110	69	23	capital	capital	NOUN
chd-110	69	24	intensive	intensive	ADJ
chd-110	69	25	.	.	PUNCT
chd-110	70	1	however	however	ADV
chd-110	70	2	the	the	DET
chd-110	70	3	benefits	benefit	NOUN
chd-110	70	4	of	of	ADP
chd-110	70	5	this	this	DET
chd-110	70	6	type	type	NOUN
chd-110	70	7	of	of	ADP
chd-110	70	8	study	study	NOUN
chd-110	70	9	remain	remain	VERB
chd-110	70	10	numerous	numerous	ADJ
chd-110	70	11	,	,	PUNCT
chd-110	70	12	including	include	VERB
chd-110	70	13	their	their	PRON
chd-110	70	14	ability	ability	NOUN
chd-110	70	15	to	to	PART
chd-110	70	16	establish	establish	VERB
chd-110	70	17	causation	causation	NOUN
chd-110	70	18	,	,	PUNCT
chd-110	70	19	assess	assess	NOUN
chd-110	70	20	impact	impact	NOUN
chd-110	70	21	of	of	ADP
chd-110	70	22	an	an	DET
chd-110	70	23	intervention	intervention	NOUN
chd-110	70	24	and	and	CCONJ
chd-110	70	25	develop	develop	VERB
chd-110	70	26	treatment	treatment	NOUN
chd-110	70	27	guidelines	guideline	NOUN
chd-110	70	28	to	to	PART
chd-110	70	29	improve	improve	VERB
chd-110	70	30	treatment	treatment	NOUN
chd-110	70	31	outcomes	outcome	NOUN
chd-110	70	32	and	and	CCONJ
chd-110	70	33	survival	survival	NOUN
chd-110	70	34	.	.	PUNCT
chd-110	71	1	(	(	PUNCT
chd-110	71	2	christensen	christensen	PROPN
chd-110	71	3	et	et	PROPN
chd-110	71	4	al	al	PROPN
chd-110	71	5	.	.	PROPN
chd-110	71	6	2007	2007	NUM
chd-110	71	7	)	)	PUNCT
chd-110	71	8	0	0	NUM
chd-110	72	1	5	5	NUM
chd-110	72	2	10	10	NUM
chd-110	72	3	15	15	NUM
chd-110	72	4	20	20	NUM
chd-110	72	5	25	25	NUM
chd-110	72	6	30	30	NUM
chd-110	72	7	35	35	NUM
chd-110	72	8	1975	1975	NUM
chd-110	72	9	1977	1977	NUM
chd-110	72	10	1979	1979	NUM
chd-110	72	11	1981	1981	NUM
chd-110	72	12	1983	1983	NUM
chd-110	72	13	1985	1985	NUM
chd-110	72	14	1987	1987	NUM
chd-110	72	15	1989	1989	NUM
chd-110	72	16	1991	1991	NUM
chd-110	72	17	1993	1993	NUM
chd-110	72	18	1995	1995	NUM
chd-110	72	19	1997	1997	NUM
chd-110	72	20	1999	1999	NUM
chd-110	72	21	2001	2001	NUM
chd-110	72	22	2003	2003	NUM
chd-110	72	23	2005	2005	NUM
chd-110	72	24	2007	2007	NUM
chd-110	72	25	2009	2009	NUM
chd-110	72	26	2011	2011	NUM
chd-110	72	27	2013	2013	NUM
chd-110	72	28	2015	2015	NUM
chd-110	72	29	2018	2018	NUM
chd-110	72	30	year	year	NOUN
chd-110	72	31	of	of	ADP
chd-110	72	32	publication	publication	NOUN
chd-110	72	33	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-110	72	34	e7	e7	PROPN
chd-110	72	35	cancer	cancer	NOUN
chd-110	72	36	health	health	NOUN
chd-110	72	37	disparities	disparity	NOUN
chd-110	72	38	research	research	VERB
chd-110	72	39	in	in	ADP
chd-110	72	40	nigeria	nigeria	PROPN
chd-110	72	41	,	,	PUNCT
chd-110	72	42	there	there	PRON
chd-110	72	43	are	be	VERB
chd-110	72	44	limited	limited	ADJ
chd-110	72	45	efforts	effort	NOUN
chd-110	72	46	to	to	PART
chd-110	72	47	foster	foster	VERB
chd-110	72	48	high	high	ADJ
chd-110	72	49	level	level	NOUN
chd-110	72	50	biomedical	biomedical	ADJ
chd-110	72	51	research	research	NOUN
chd-110	72	52	.	.	PUNCT
chd-110	73	1	these	these	DET
chd-110	73	2	efforts	effort	NOUN
chd-110	73	3	are	be	AUX
chd-110	73	4	often	often	ADV
chd-110	73	5	led	lead	VERB
chd-110	73	6	by	by	ADP
chd-110	73	7	established	establish	VERB
chd-110	73	8	consortia	consortium	NOUN
chd-110	73	9	focused	focus	VERB
chd-110	73	10	on	on	ADP
chd-110	73	11	specific	specific	ADJ
chd-110	73	12	research	research	NOUN
chd-110	73	13	goals	goal	NOUN
chd-110	73	14	.	.	PUNCT
chd-110	74	1	for	for	ADP
chd-110	74	2	example	example	NOUN
chd-110	74	3	,	,	PUNCT
chd-110	74	4	the	the	DET
chd-110	74	5	prostate	prostate	NOUN
chd-110	74	6	cancer	cancer	NOUN
chd-110	74	7	transatlantic	transatlantic	ADJ
chd-110	74	8	consortium	consortium	NOUN
chd-110	74	9	(	(	PUNCT
chd-110	74	10	captc	captc	PROPN
chd-110	74	11	)	)	PUNCT
chd-110	74	12	,	,	PUNCT
chd-110	74	13	established	establish	VERB
chd-110	74	14	in	in	ADP
chd-110	74	15	2005	2005	NUM
chd-110	74	16	,	,	PUNCT
chd-110	74	17	has	have	AUX
chd-110	74	18	supported	support	VERB
chd-110	74	19	prostate	prostate	NOUN
chd-110	74	20	cancer	cancer	NOUN
chd-110	74	21	research	research	NOUN
chd-110	74	22	in	in	ADP
chd-110	74	23	nigeria	nigeria	PROPN
chd-110	74	24	since	since	SCONJ
chd-110	74	25	2006	2006	NUM
chd-110	74	26	(	(	PUNCT
chd-110	74	27	https://epi.grants.cancer.gov/	https://epi.grants.cancer.gov/	PROPN
chd-110	74	28	captc/	captc/	NUM
chd-110	74	29	)	)	PUNCT
chd-110	74	30	.	.	PUNCT
chd-110	75	1	captc	captc	PROPN
chd-110	75	2	is	be	AUX
chd-110	75	3	a	a	DET
chd-110	75	4	national	national	ADJ
chd-110	75	5	cancer	cancer	PROPN
chd-110	75	6	institute	institute	PROPN
chd-110	75	7	(	(	PUNCT
chd-110	75	8	nci	nci	PROPN
chd-110	75	9	)	)	PUNCT
chd-110	75	10	epidemiology	epidemiology	NOUN
chd-110	75	11	and	and	CCONJ
chd-110	75	12	genomics	genomics	NOUN
chd-110	75	13	research	research	NOUN
chd-110	75	14	program	program	NOUN
chd-110	75	15	(	(	PUNCT
chd-110	75	16	egrp	egrp	PROPN
chd-110	75	17	)	)	PUNCT
chd-110	75	18	supported	support	VERB
chd-110	75	19	consortium	consortium	NOUN
chd-110	75	20	.	.	PUNCT
chd-110	76	1	captc	captc	PROPN
chd-110	76	2	has	have	VERB
chd-110	76	3	over	over	ADP
chd-110	76	4	150	150	NUM
chd-110	76	5	members	member	NOUN
chd-110	76	6	who	who	PRON
chd-110	76	7	are	be	AUX
chd-110	76	8	prostate	prostate	NOUN
chd-110	76	9	scientists	scientist	NOUN
chd-110	76	10	,	,	PUNCT
chd-110	76	11	clinicians	clinician	NOUN
chd-110	76	12	,	,	PUNCT
chd-110	76	13	and	and	CCONJ
chd-110	76	14	consumer	consumer	NOUN
chd-110	76	15	advocates	advocate	NOUN
chd-110	76	16	from	from	ADP
chd-110	76	17	countries	country	NOUN
chd-110	76	18	connected	connect	VERB
chd-110	76	19	by	by	ADP
chd-110	76	20	the	the	DET
chd-110	76	21	transatlantic	transatlantic	ADJ
chd-110	76	22	slave	slave	NOUN
chd-110	76	23	trade	trade	NOUN
chd-110	76	24	,	,	PUNCT
chd-110	76	25	including	include	VERB
chd-110	76	26	north	north	PROPN
chd-110	76	27	america	america	PROPN
chd-110	76	28	,	,	PUNCT
chd-110	76	29	europe	europe	PROPN
chd-110	76	30	,	,	PUNCT
chd-110	76	31	the	the	DET
chd-110	76	32	caribbean	caribbean	ADJ
chd-110	76	33	,	,	PUNCT
chd-110	76	34	and	and	CCONJ
chd-110	76	35	africa	africa	PROPN
chd-110	76	36	countries	countries	PROPN
chd-110	76	37	.	.	PUNCT
chd-110	77	1	captc	captc	PROPN
chd-110	77	2	investigators	investigator	NOUN
chd-110	77	3	collaborate	collaborate	VERB
chd-110	77	4	on	on	ADP
chd-110	77	5	projects	project	NOUN
chd-110	77	6	based	base	VERB
chd-110	77	7	on	on	ADP
chd-110	77	8	the	the	DET
chd-110	77	9	following	follow	VERB
chd-110	77	10	scientific	scientific	ADJ
chd-110	77	11	aims	aim	NOUN
chd-110	77	12	:	:	PUNCT
chd-110	77	13	1	1	X
chd-110	77	14	.	.	X
chd-110	77	15	explore	explore	VERB
chd-110	77	16	and	and	CCONJ
chd-110	77	17	quantify	quantify	VERB
chd-110	77	18	the	the	DET
chd-110	77	19	magnitude	magnitude	NOUN
chd-110	77	20	of	of	ADP
chd-110	77	21	prostate	prostate	NOUN
chd-110	77	22	cancer	cancer	NOUN
chd-110	77	23	morbidity	morbidity	NOUN
chd-110	77	24	and	and	CCONJ
chd-110	77	25	mortality	mortality	NOUN
chd-110	77	26	variance	variance	NOUN
chd-110	77	27	among	among	ADP
chd-110	77	28	black	black	ADJ
chd-110	77	29	men	man	NOUN
chd-110	77	30	of	of	ADP
chd-110	77	31	african	african	ADJ
chd-110	77	32	ancestry	ancestry	NOUN
chd-110	77	33	;	;	PUNCT
chd-110	77	34	2	2	X
chd-110	77	35	.	.	X
chd-110	77	36	explore	explore	VERB
chd-110	77	37	genetic	genetic	ADJ
chd-110	77	38	,	,	PUNCT
chd-110	77	39	environmental	environmental	ADJ
chd-110	77	40	and	and	CCONJ
chd-110	77	41	behavioral	behavioral	ADJ
chd-110	77	42	etiology	etiology	NOUN
chd-110	77	43	of	of	ADP
chd-110	77	44	this	this	DET
chd-110	77	45	variance	variance	NOUN
chd-110	77	46	;	;	PUNCT
chd-110	77	47	and	and	CCONJ
chd-110	77	48	3	3	X
chd-110	77	49	.	.	X
chd-110	77	50	develop	develop	VERB
chd-110	77	51	community	community	NOUN
chd-110	77	52	-	-	PUNCT
chd-110	77	53	sensitive	sensitive	ADJ
chd-110	77	54	initiatives	initiative	NOUN
chd-110	77	55	to	to	PART
chd-110	77	56	control	control	VERB
chd-110	77	57	prostate	prostate	NOUN
chd-110	77	58	cancer	cancer	NOUN
chd-110	77	59	globally	globally	ADV
chd-110	77	60	.	.	PUNCT
chd-110	78	1	the	the	DET
chd-110	78	2	official	official	ADJ
chd-110	78	3	scientific	scientific	ADJ
chd-110	78	4	conference	conference	NOUN
chd-110	78	5	for	for	ADP
chd-110	78	6	the	the	DET
chd-110	78	7	captc	captc	NOUN
chd-110	78	8	is	be	AUX
chd-110	78	9	the	the	DET
chd-110	78	10	biennial	biennial	ADJ
chd-110	78	11	science	science	NOUN
chd-110	78	12	of	of	ADP
chd-110	78	13	global	global	ADJ
chd-110	78	14	prostate	prostate	NOUN
chd-110	78	15	cancer	cancer	NOUN
chd-110	78	16	conference	conference	NOUN
chd-110	78	17	for	for	ADP
chd-110	78	18	black	black	ADJ
chd-110	78	19	men	man	NOUN
chd-110	78	20	,	,	PUNCT
chd-110	78	21	which	which	PRON
chd-110	78	22	was	be	AUX
chd-110	78	23	held	hold	VERB
chd-110	78	24	in	in	ADP
chd-110	78	25	jacksonville	jacksonville	PROPN
chd-110	78	26	(	(	PUNCT
chd-110	78	27	usa	usa	PROPN
chd-110	78	28	)	)	PUNCT
chd-110	78	29	in	in	ADP
chd-110	78	30	2010	2010	NUM
chd-110	78	31	,	,	PUNCT
chd-110	78	32	nassau	nassau	PROPN
chd-110	78	33	(	(	PUNCT
chd-110	78	34	bahamas	bahamas	PROPN
chd-110	78	35	)	)	PUNCT
chd-110	78	36	in	in	ADP
chd-110	78	37	2012	2012	NUM
chd-110	78	38	,	,	PUNCT
chd-110	78	39	montego	montego	PROPN
chd-110	78	40	bay	bay	PROPN
chd-110	78	41	(	(	PUNCT
chd-110	78	42	jamaica	jamaica	PROPN
chd-110	78	43	)	)	PUNCT
chd-110	78	44	in	in	ADP
chd-110	78	45	2014	2014	NUM
chd-110	78	46	,	,	PUNCT
chd-110	78	47	orlando	orlando	PROPN
chd-110	78	48	(	(	PUNCT
chd-110	78	49	usa	usa	PROPN
chd-110	78	50	)	)	PUNCT
chd-110	78	51	in	in	ADP
chd-110	78	52	2016	2016	NUM
chd-110	78	53	,	,	PUNCT
chd-110	78	54	and	and	CCONJ
chd-110	78	55	will	will	AUX
chd-110	78	56	be	be	AUX
chd-110	78	57	held	hold	VERB
chd-110	78	58	in	in	ADP
chd-110	78	59	ilorin	ilorin	PROPN
chd-110	78	60	(	(	PUNCT
chd-110	78	61	nigeria	nigeria	PROPN
chd-110	78	62	)	)	PUNCT
chd-110	78	63	in	in	ADP
chd-110	78	64	2018	2018	NUM
chd-110	78	65	.	.	PUNCT
chd-110	79	1	other	other	ADJ
chd-110	79	2	active	active	ADJ
chd-110	79	3	consortia	consortium	NOUN
chd-110	79	4	in	in	ADP
chd-110	79	5	nigeria	nigeria	PROPN
chd-110	79	6	are	be	AUX
chd-110	79	7	the	the	DET
chd-110	79	8	african	african	ADJ
chd-110	79	9	colorectal	colorectal	ADJ
chd-110	79	10	cancer	cancer	NOUN
chd-110	79	11	group	group	NOUN
chd-110	79	12	(	(	PUNCT
chd-110	79	13	argo	argo	PROPN
chd-110	79	14	)	)	PUNCT
chd-110	79	15	,	,	PUNCT
chd-110	79	16	the	the	DET
chd-110	79	17	men	man	NOUN
chd-110	79	18	of	of	ADP
chd-110	79	19	african	african	ADJ
chd-110	79	20	descent	descent	NOUN
chd-110	79	21	and	and	CCONJ
chd-110	79	22	carcinoma	carcinoma	NOUN
chd-110	79	23	of	of	ADP
chd-110	79	24	the	the	DET
chd-110	79	25	prostate	prostate	NOUN
chd-110	79	26	(	(	PUNCT
chd-110	79	27	madcap	madcap	NOUN
chd-110	79	28	)	)	PUNCT
chd-110	79	29	,	,	PUNCT
chd-110	79	30	and	and	CCONJ
chd-110	79	31	breast	breast	NOUN
chd-110	79	32	cancer	cancer	NOUN
chd-110	79	33	consortium	consortium	NOUN
chd-110	79	34	.	.	PUNCT
chd-110	80	1	the	the	DET
chd-110	80	2	commonest	commonest	NOUN
chd-110	80	3	level	level	NOUN
chd-110	80	4	of	of	ADP
chd-110	80	5	evidence	evidence	NOUN
chd-110	80	6	of	of	ADP
chd-110	80	7	prostate	prostate	NOUN
chd-110	80	8	cancer	cancer	NOUN
chd-110	80	9	in	in	ADP
chd-110	80	10	this	this	DET
chd-110	80	11	review	review	NOUN
chd-110	80	12	is	be	AUX
chd-110	80	13	level	level	NOUN
chd-110	80	14	4	4	NUM
chd-110	80	15	,	,	PUNCT
chd-110	80	16	which	which	PRON
chd-110	80	17	includes	include	VERB
chd-110	80	18	:	:	PUNCT
chd-110	80	19	the	the	DET
chd-110	80	20	case	case	NOUN
chd-110	80	21	reports	report	VERB
chd-110	80	22	,	,	PUNCT
chd-110	80	23	case	case	NOUN
chd-110	80	24	series	series	NOUN
chd-110	80	25	,	,	PUNCT
chd-110	80	26	and	and	CCONJ
chd-110	80	27	cross	cross	ADJ
chd-110	80	28	-	-	ADJ
chd-110	80	29	sectional	sectional	ADJ
chd-110	80	30	studies	study	NOUN
chd-110	80	31	.	.	PUNCT
chd-110	81	1	these	these	DET
chd-110	81	2	levels	level	NOUN
chd-110	81	3	of	of	ADP
chd-110	81	4	evidence	evidence	NOUN
chd-110	81	5	are	be	AUX
chd-110	81	6	relatively	relatively	ADV
chd-110	81	7	low	low	ADJ
chd-110	81	8	and	and	CCONJ
chd-110	81	9	are	be	AUX
chd-110	81	10	less	less	ADV
chd-110	81	11	likely	likely	ADJ
chd-110	81	12	to	to	PART
chd-110	81	13	be	be	AUX
chd-110	81	14	adopted	adopt	VERB
chd-110	81	15	in	in	ADP
chd-110	81	16	developing	develop	VERB
chd-110	81	17	treatment	treatment	NOUN
chd-110	81	18	guidelines	guideline	NOUN
chd-110	81	19	.	.	PUNCT
chd-110	82	1	most	most	ADJ
chd-110	82	2	international	international	ADJ
chd-110	82	3	treatment	treatment	NOUN
chd-110	82	4	guidelines	guideline	NOUN
chd-110	82	5	are	be	AUX
chd-110	82	6	developed	develop	VERB
chd-110	82	7	based	base	VERB
chd-110	82	8	on	on	ADP
chd-110	82	9	level	level	NOUN
chd-110	82	10	1	1	NUM
chd-110	82	11	evidence	evidence	NOUN
chd-110	82	12	,	,	PUNCT
chd-110	82	13	clinical	clinical	ADJ
chd-110	82	14	trials	trial	NOUN
chd-110	82	15	.	.	PUNCT
chd-110	83	1	they	they	PRON
chd-110	83	2	analyse	analyse	VERB
chd-110	83	3	results	result	VERB
chd-110	83	4	from	from	ADP
chd-110	83	5	these	these	DET
chd-110	83	6	clinical	clinical	ADJ
chd-110	83	7	trials	trial	NOUN
chd-110	83	8	conducted	conduct	VERB
chd-110	83	9	on	on	ADP
chd-110	83	10	prostate	prostate	NOUN
chd-110	83	11	cancer	cancer	NOUN
chd-110	83	12	patients	patient	NOUN
chd-110	83	13	in	in	ADP
chd-110	83	14	their	their	PRON
chd-110	83	15	countries	country	NOUN
chd-110	83	16	and	and	CCONJ
chd-110	83	17	then	then	ADV
chd-110	83	18	adapt	adapt	VERB
chd-110	83	19	them	they	PRON
chd-110	83	20	in	in	ADP
chd-110	83	21	the	the	DET
chd-110	83	22	development	development	NOUN
chd-110	83	23	of	of	ADP
chd-110	83	24	treatment	treatment	NOUN
chd-110	83	25	guidelines	guideline	NOUN
chd-110	83	26	.	.	PUNCT
chd-110	84	1	an	an	DET
chd-110	84	2	example	example	NOUN
chd-110	84	3	is	be	AUX
chd-110	84	4	the	the	DET
chd-110	84	5	stampede	stampede	NOUN
chd-110	84	6	trial	trial	NOUN
chd-110	84	7	in	in	ADP
chd-110	84	8	the	the	DET
chd-110	84	9	uk	uk	PROPN
chd-110	84	10	(	(	PUNCT
chd-110	84	11	james	james	PROPN
chd-110	84	12	et	et	PROPN
chd-110	84	13	al	al	PROPN
chd-110	84	14	.	.	PROPN
chd-110	84	15	2015	2015	NUM
chd-110	84	16	)	)	PUNCT
chd-110	84	17	which	which	PRON
chd-110	84	18	has	have	AUX
chd-110	84	19	led	lead	VERB
chd-110	84	20	to	to	ADP
chd-110	84	21	changes	change	NOUN
chd-110	84	22	in	in	ADP
chd-110	84	23	the	the	DET
chd-110	84	24	standard	standard	NOUN
chd-110	84	25	of	of	ADP
chd-110	84	26	care	care	NOUN
chd-110	84	27	of	of	ADP
chd-110	84	28	prostate	prostate	NOUN
chd-110	84	29	cancer	cancer	NOUN
chd-110	84	30	patients	patient	NOUN
chd-110	84	31	in	in	ADP
chd-110	84	32	the	the	DET
chd-110	84	33	uk	uk	PROPN
chd-110	84	34	another	another	PRON
chd-110	84	35	is	be	AUX
chd-110	84	36	the	the	DET
chd-110	84	37	chattered	chatter	VERB
chd-110	84	38	trial	trial	NOUN
chd-110	84	39	(	(	PUNCT
chd-110	84	40	sweeney	sweeney	PROPN
chd-110	84	41	et	et	PROPN
chd-110	84	42	al	al	PROPN
chd-110	84	43	.	.	PROPN
chd-110	84	44	2015	2015	NUM
chd-110	84	45	)	)	PUNCT
chd-110	84	46	,	,	PUNCT
chd-110	84	47	a	a	DET
chd-110	84	48	similar	similar	ADJ
chd-110	84	49	clinical	clinical	ADJ
chd-110	84	50	trial	trial	NOUN
chd-110	84	51	as	as	ADP
chd-110	84	52	the	the	DET
chd-110	84	53	stampede	stampede	NOUN
chd-110	84	54	,	,	PUNCT
chd-110	84	55	which	which	PRON
chd-110	84	56	was	be	AUX
chd-110	84	57	conducted	conduct	VERB
chd-110	84	58	in	in	ADP
chd-110	84	59	the	the	DET
chd-110	84	60	usa	usa	PROPN
chd-110	84	61	.	.	PROPN
chd-110	85	1	clinical	clinical	ADJ
chd-110	85	2	trials	trial	NOUN
chd-110	85	3	have	have	AUX
chd-110	85	4	always	always	ADV
chd-110	85	5	sharpened	sharpen	VERB
chd-110	85	6	the	the	DET
chd-110	85	7	paradigms	paradigm	NOUN
chd-110	85	8	of	of	ADP
chd-110	85	9	treatment	treatment	NOUN
chd-110	85	10	internationally	internationally	ADV
chd-110	85	11	.	.	PUNCT
chd-110	86	1	the	the	DET
chd-110	86	2	study	study	NOUN
chd-110	86	3	showed	show	VERB
chd-110	86	4	a	a	DET
chd-110	86	5	steep	steep	ADJ
chd-110	86	6	increase	increase	NOUN
chd-110	86	7	in	in	ADP
chd-110	86	8	publications	publication	NOUN
chd-110	86	9	on	on	ADP
chd-110	86	10	prostate	prostate	NOUN
chd-110	86	11	cancer	cancer	NOUN
chd-110	86	12	in	in	ADP
chd-110	86	13	nigeria	nigeria	PROPN
chd-110	86	14	from	from	ADP
chd-110	86	15	the	the	DET
chd-110	86	16	year	year	NOUN
chd-110	86	17	2000	2000	NUM
chd-110	86	18	to	to	ADP
chd-110	86	19	date	date	NOUN
chd-110	86	20	.	.	PUNCT
chd-110	87	1	despite	despite	SCONJ
chd-110	87	2	this	this	DET
chd-110	87	3	increase	increase	NOUN
chd-110	87	4	the	the	DET
chd-110	87	5	proportion	proportion	NOUN
chd-110	87	6	remains	remain	VERB
chd-110	87	7	very	very	ADV
chd-110	87	8	low	low	ADJ
chd-110	87	9	when	when	SCONJ
chd-110	87	10	compared	compare	VERB
chd-110	87	11	to	to	ADP
chd-110	87	12	prostate	prostate	NOUN
chd-110	87	13	cancer	cancer	NOUN
chd-110	87	14	studies	study	NOUN
chd-110	87	15	in	in	ADP
chd-110	87	16	other	other	ADJ
chd-110	87	17	countries	country	NOUN
chd-110	87	18	.	.	PUNCT
chd-110	88	1	the	the	DET
chd-110	88	2	highest	high	ADJ
chd-110	88	3	number	number	NOUN
chd-110	88	4	of	of	ADP
chd-110	88	5	publications	publication	NOUN
chd-110	88	6	was	be	AUX
chd-110	88	7	published	publish	VERB
chd-110	88	8	in	in	ADP
chd-110	88	9	2017	2017	NUM
chd-110	88	10	,	,	PUNCT
chd-110	88	11	when	when	SCONJ
chd-110	88	12	a	a	DET
chd-110	88	13	total	total	NOUN
chd-110	88	14	of	of	ADP
chd-110	88	15	29	29	NUM
chd-110	88	16	articles	article	NOUN
chd-110	88	17	were	be	AUX
chd-110	88	18	published	publish	VERB
chd-110	88	19	on	on	ADP
chd-110	88	20	prostate	prostate	NOUN
chd-110	88	21	cancer	cancer	NOUN
chd-110	88	22	.	.	PUNCT
chd-110	89	1	when	when	SCONJ
chd-110	89	2	compared	compare	VERB
chd-110	89	3	with	with	ADP
chd-110	89	4	other	other	ADJ
chd-110	89	5	parts	part	NOUN
chd-110	89	6	of	of	ADP
chd-110	89	7	the	the	DET
chd-110	89	8	world	world	NOUN
chd-110	89	9	,	,	PUNCT
chd-110	89	10	the	the	DET
chd-110	89	11	usa	usa	PROPN
chd-110	89	12	and	and	CCONJ
chd-110	89	13	uk	uk	PROPN
chd-110	89	14	uniquely	uniquely	ADV
chd-110	89	15	had	have	VERB
chd-110	89	16	over	over	ADP
chd-110	89	17	300	300	NUM
chd-110	89	18	publications	publication	NOUN
chd-110	89	19	on	on	ADP
chd-110	89	20	prostate	prostate	NOUN
chd-110	89	21	cancer	cancer	NOUN
chd-110	89	22	on	on	ADP
chd-110	89	23	pubmed	pubmed	PROPN
chd-110	89	24	search	search	NOUN
chd-110	89	25	engine	engine	NOUN
chd-110	89	26	in	in	ADP
chd-110	89	27	2017	2017	NUM
chd-110	89	28	.	.	PUNCT
chd-110	90	1	a	a	DET
chd-110	90	2	major	major	ADJ
chd-110	90	3	reason	reason	NOUN
chd-110	90	4	for	for	ADP
chd-110	90	5	low	low	ADJ
chd-110	90	6	levels	level	NOUN
chd-110	90	7	of	of	ADP
chd-110	90	8	prostate	prostate	NOUN
chd-110	90	9	cancer	cancer	NOUN
chd-110	90	10	research	research	NOUN
chd-110	90	11	in	in	ADP
chd-110	90	12	nigeria	nigeria	PROPN
chd-110	90	13	is	be	AUX
chd-110	90	14	the	the	DET
chd-110	90	15	low	low	ADJ
chd-110	90	16	funding	funding	NOUN
chd-110	90	17	available	available	ADJ
chd-110	90	18	for	for	ADP
chd-110	90	19	cancer	cancer	NOUN
chd-110	90	20	research	research	NOUN
chd-110	90	21	from	from	ADP
chd-110	90	22	public	public	ADJ
chd-110	90	23	and	and	CCONJ
chd-110	90	24	private	private	ADJ
chd-110	90	25	agencies	agency	NOUN
chd-110	90	26	/	/	SYM
chd-110	90	27	organizations	organization	NOUN
chd-110	90	28	.	.	PUNCT
chd-110	91	1	a	a	DET
chd-110	91	2	major	major	ADJ
chd-110	91	3	funding	funding	NOUN
chd-110	91	4	channel	channel	NOUN
chd-110	91	5	for	for	ADP
chd-110	91	6	research	research	NOUN
chd-110	91	7	in	in	ADP
chd-110	91	8	nigeria	nigeria	PROPN
chd-110	91	9	is	be	AUX
chd-110	91	10	the	the	DET
chd-110	91	11	tertiary	tertiary	ADJ
chd-110	91	12	education	education	NOUN
chd-110	91	13	trust	trust	NOUN
chd-110	91	14	fund	fund	PROPN
chd-110	91	15	(	(	PUNCT
chd-110	91	16	tetfund	tetfund	NOUN
chd-110	91	17	)	)	PUNCT
chd-110	91	18	established	establish	VERB
chd-110	91	19	under	under	ADP
chd-110	91	20	the	the	DET
chd-110	91	21	tetfund	tetfund	NOUN
chd-110	91	22	act	act	NOUN
chd-110	91	23	(	(	PUNCT
chd-110	91	24	tertiary	tertiary	ADJ
chd-110	91	25	education	education	NOUN
chd-110	91	26	trust	trust	NOUN
chd-110	91	27	fund	fund	PROPN
chd-110	91	28	)	)	PUNCT
chd-110	91	29	in	in	ADP
chd-110	91	30	2011	2011	NUM
chd-110	91	31	.	.	PUNCT
chd-110	92	1	tetfund	tetfund	NOUN
chd-110	92	2	gets	get	VERB
chd-110	92	3	the	the	DET
chd-110	92	4	funding	funding	NOUN
chd-110	92	5	by	by	ADP
chd-110	92	6	imposing	impose	VERB
chd-110	92	7	a	a	DET
chd-110	92	8	2	2	NUM
chd-110	92	9	%	%	NOUN
chd-110	92	10	education	education	NOUN
chd-110	92	11	tax	tax	NOUN
chd-110	92	12	on	on	ADP
chd-110	92	13	all	all	DET
chd-110	92	14	registered	register	VERB
chd-110	92	15	companies	company	NOUN
chd-110	92	16	in	in	ADP
chd-110	92	17	nigeria	nigeria	PROPN
chd-110	92	18	.	.	PUNCT
chd-110	93	1	the	the	DET
chd-110	93	2	fund	fund	NOUN
chd-110	93	3	is	be	AUX
chd-110	93	4	disbursed	disburse	VERB
chd-110	93	5	to	to	ADP
chd-110	93	6	tertiary	tertiary	ADJ
chd-110	93	7	educational	educational	ADJ
chd-110	93	8	institutions	institution	NOUN
chd-110	93	9	at	at	ADP
chd-110	93	10	federal	federal	ADJ
chd-110	93	11	and	and	CCONJ
chd-110	93	12	state	state	NOUN
chd-110	93	13	levels	level	NOUN
chd-110	93	14	as	as	ADP
chd-110	93	15	research	research	NOUN
chd-110	93	16	grants	grant	NOUN
chd-110	93	17	in	in	ADP
chd-110	93	18	all	all	DET
chd-110	93	19	fields	field	NOUN
chd-110	93	20	(	(	PUNCT
chd-110	93	21	tetfund	tetfund	NOUN
chd-110	93	22	2014	2014	NUM
chd-110	93	23	)	)	PUNCT
chd-110	93	24	.	.	PUNCT
chd-110	94	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-110	94	2	e8	e8	PROPN
chd-110	94	3	cancer	cancer	PROPN
chd-110	94	4	health	health	NOUN
chd-110	94	5	disparities	disparity	NOUN
chd-110	94	6	research	research	VERB
chd-110	94	7	however	however	ADV
chd-110	94	8	,	,	PUNCT
chd-110	94	9	the	the	DET
chd-110	94	10	rising	rise	VERB
chd-110	94	11	trend	trend	NOUN
chd-110	94	12	of	of	ADP
chd-110	94	13	cancers	cancer	NOUN
chd-110	94	14	in	in	ADP
chd-110	94	15	nigeria	nigeria	PROPN
chd-110	94	16	necessitates	necessitate	VERB
chd-110	94	17	an	an	DET
chd-110	94	18	increase	increase	NOUN
chd-110	94	19	in	in	ADP
chd-110	94	20	cancer	cancer	NOUN
chd-110	94	21	research	research	NOUN
chd-110	94	22	funding	funding	NOUN
chd-110	94	23	as	as	SCONJ
chd-110	94	24	exemplified	exemplify	VERB
chd-110	94	25	by	by	ADP
chd-110	94	26	developed	develop	VERB
chd-110	94	27	countries	country	NOUN
chd-110	94	28	.	.	PUNCT
chd-110	95	1	developed	develop	VERB
chd-110	95	2	countries	country	NOUN
chd-110	95	3	have	have	VERB
chd-110	95	4	several	several	ADJ
chd-110	95	5	funding	funding	NOUN
chd-110	95	6	channels	channel	NOUN
chd-110	95	7	for	for	ADP
chd-110	95	8	research	research	NOUN
chd-110	95	9	.	.	PUNCT
chd-110	96	1	these	these	PRON
chd-110	96	2	include	include	VERB
chd-110	96	3	government	government	NOUN
chd-110	96	4	funding	funding	NOUN
chd-110	96	5	and	and	CCONJ
chd-110	96	6	,	,	PUNCT
chd-110	96	7	non	non	ADJ
chd-110	96	8	-	-	ADJ
chd-110	96	9	governmental	governmental	ADJ
chd-110	96	10	organisations	organisation	NOUN
chd-110	96	11	and	and	CCONJ
chd-110	96	12	charities	charity	NOUN
chd-110	96	13	.	.	PUNCT
chd-110	97	1	in	in	ADP
chd-110	97	2	the	the	DET
chd-110	97	3	united	united	PROPN
chd-110	97	4	states	states	PROPN
chd-110	97	5	,	,	PUNCT
chd-110	97	6	the	the	DET
chd-110	97	7	2017	2017	NUM
chd-110	97	8	budget	budget	NOUN
chd-110	97	9	allocated	allocate	VERB
chd-110	97	10	$	$	SYM
chd-110	97	11	33.1	33.1	NUM
chd-110	97	12	billion	billion	NUM
chd-110	97	13	(	(	PUNCT
chd-110	97	14	0.8	0.8	NUM
chd-110	97	15	%	%	NOUN
chd-110	97	16	)	)	PUNCT
chd-110	97	17	,	,	PUNCT
chd-110	97	18	out	out	ADP
chd-110	97	19	of	of	ADP
chd-110	97	20	the	the	DET
chd-110	97	21	$	$	SYM
chd-110	97	22	4.2	4.2	NUM
chd-110	97	23	trillion	trillion	NUM
chd-110	97	24	to	to	ADP
chd-110	97	25	the	the	DET
chd-110	97	26	national	national	PROPN
chd-110	97	27	institute	institute	PROPN
chd-110	97	28	of	of	ADP
chd-110	97	29	health	health	PROPN
chd-110	97	30	to	to	PART
chd-110	97	31	accelerate	accelerate	VERB
chd-110	97	32	groundbreaking	groundbreake	VERB
chd-110	97	33	research	research	NOUN
chd-110	97	34	on	on	ADP
chd-110	97	35	cancer	cancer	NOUN
chd-110	97	36	,	,	PUNCT
chd-110	97	37	precision	precision	NOUN
chd-110	97	38	medicine	medicine	NOUN
chd-110	97	39	and	and	CCONJ
chd-110	97	40	others	other	NOUN
chd-110	97	41	(	(	PUNCT
chd-110	97	42	sargent	sargent	PROPN
chd-110	97	43	et	et	PROPN
chd-110	97	44	al	al	PROPN
chd-110	97	45	.	.	PROPN
chd-110	97	46	2017	2017	NUM
chd-110	97	47	)	)	PUNCT
chd-110	97	48	.	.	PUNCT
chd-110	98	1	in	in	ADP
chd-110	98	2	the	the	DET
chd-110	98	3	uk	uk	PROPN
chd-110	98	4	,	,	PUNCT
chd-110	98	5	the	the	DET
chd-110	98	6	total	total	ADJ
chd-110	98	7	investment	investment	NOUN
chd-110	98	8	is	be	AUX
chd-110	98	9	£	£	SYM
chd-110	98	10	26.3	26.3	NUM
chd-110	98	11	billion	billion	NUM
chd-110	98	12	between	between	ADP
chd-110	98	13	2016/17	2016/17	NUM
chd-110	98	14	to	to	ADP
chd-110	98	15	2020/21	2020/21	NUM
chd-110	98	16	with	with	ADP
chd-110	98	17	an	an	DET
chd-110	98	18	average	average	NOUN
chd-110	98	19	of	of	ADP
chd-110	98	20	£	£	SYM
chd-110	98	21	5	5	NUM
chd-110	98	22	billion	billion	NUM
chd-110	98	23	pounds	pound	NOUN
chd-110	98	24	yearly	yearly	ADV
chd-110	98	25	as	as	ADP
chd-110	98	26	allocations	allocation	NOUN
chd-110	98	27	for	for	ADP
chd-110	98	28	the	the	DET
chd-110	98	29	science	science	NOUN
chd-110	98	30	and	and	CCONJ
chd-110	98	31	research	research	NOUN
chd-110	98	32	in	in	ADP
chd-110	98	33	the	the	DET
chd-110	98	34	budget	budget	NOUN
chd-110	98	35	(	(	PUNCT
chd-110	98	36	hm	hm	INTJ
chd-110	98	37	government	government	NOUN
chd-110	98	38	2016	2016	NUM
chd-110	98	39	)	)	PUNCT
chd-110	98	40	.	.	PUNCT
chd-110	99	1	it	it	PRON
chd-110	99	2	is	be	AUX
chd-110	99	3	therefore	therefore	ADV
chd-110	99	4	not	not	PART
chd-110	99	5	surprising	surprising	ADJ
chd-110	99	6	that	that	SCONJ
chd-110	99	7	prostate	prostate	NOUN
chd-110	99	8	cancer	cancer	NOUN
chd-110	99	9	survival	survival	NOUN
chd-110	99	10	has	have	AUX
chd-110	99	11	improved	improve	VERB
chd-110	99	12	in	in	ADP
chd-110	99	13	both	both	PRON
chd-110	99	14	united	united	PROPN
chd-110	99	15	states	states	PROPN
chd-110	99	16	and	and	CCONJ
chd-110	99	17	uk	uk	PROPN
chd-110	99	18	.	.	PROPN
chd-110	99	19	to	to	PART
chd-110	99	20	make	make	VERB
chd-110	99	21	significant	significant	ADJ
chd-110	99	22	leap	leap	NOUN
chd-110	99	23	in	in	ADP
chd-110	99	24	fighting	fight	VERB
chd-110	99	25	prostate	prostate	NOUN
chd-110	99	26	cancer	cancer	NOUN
chd-110	99	27	in	in	ADP
chd-110	99	28	nigeria	nigeria	PROPN
chd-110	99	29	,	,	PUNCT
chd-110	99	30	there	there	PRON
chd-110	99	31	needs	need	VERB
chd-110	99	32	to	to	PART
chd-110	99	33	be	be	AUX
chd-110	99	34	focus	focus	VERB
chd-110	99	35	on	on	ADP
chd-110	99	36	funding	fund	VERB
chd-110	99	37	prostate	prostate	NOUN
chd-110	99	38	cancer	cancer	NOUN
chd-110	99	39	research	research	NOUN
chd-110	99	40	.	.	PUNCT
chd-110	100	1	while	while	SCONJ
chd-110	100	2	it	it	PRON
chd-110	100	3	will	will	AUX
chd-110	100	4	greatly	greatly	ADV
chd-110	100	5	help	help	VERB
chd-110	100	6	to	to	PART
chd-110	100	7	have	have	VERB
chd-110	100	8	governmental	governmental	ADJ
chd-110	100	9	funding	funding	NOUN
chd-110	100	10	,	,	PUNCT
chd-110	100	11	corporate	corporate	ADJ
chd-110	100	12	and	and	CCONJ
chd-110	100	13	philanthropic	philanthropic	NOUN
chd-110	100	14	giving	giving	NOUN
chd-110	100	15	will	will	AUX
chd-110	100	16	also	also	ADV
chd-110	100	17	be	be	AUX
chd-110	100	18	very	very	ADV
chd-110	100	19	important	important	ADJ
chd-110	100	20	.	.	PUNCT
chd-110	101	1	in	in	ADP
chd-110	101	2	september	september	PROPN
chd-110	101	3	2005	2005	NUM
chd-110	101	4	,	,	PUNCT
chd-110	101	5	the	the	DET
chd-110	101	6	foundation	foundation	NOUN
chd-110	101	7	for	for	ADP
chd-110	101	8	carcinoma	carcinoma	NOUN
chd-110	101	9	of	of	ADP
chd-110	101	10	the	the	DET
chd-110	101	11	prostate	prostate	NOUN
chd-110	101	12	transatlantic	transatlantic	ADJ
chd-110	101	13	research	research	NOUN
chd-110	101	14	was	be	AUX
chd-110	101	15	established	establish	VERB
chd-110	101	16	to	to	PART
chd-110	101	17	accelerate	accelerate	VERB
chd-110	101	18	prostate	prostate	NOUN
chd-110	101	19	cancer	cancer	NOUN
chd-110	101	20	research	research	NOUN
chd-110	101	21	in	in	ADP
chd-110	101	22	nigeria	nigeria	PROPN
chd-110	101	23	.	.	PUNCT
chd-110	102	1	this	this	DET
chd-110	102	2	foundation	foundation	NOUN
chd-110	102	3	is	be	AUX
chd-110	102	4	a	a	DET
chd-110	102	5	step	step	NOUN
chd-110	102	6	in	in	ADP
chd-110	102	7	the	the	DET
chd-110	102	8	right	right	ADJ
chd-110	102	9	way	way	NOUN
chd-110	102	10	to	to	PART
chd-110	102	11	raise	raise	VERB
chd-110	102	12	the	the	DET
chd-110	102	13	profile	profile	NOUN
chd-110	102	14	of	of	ADP
chd-110	102	15	prostate	prostate	NOUN
chd-110	102	16	cancer	cancer	NOUN
chd-110	102	17	research	research	NOUN
chd-110	102	18	in	in	ADP
chd-110	102	19	nigeria	nigeria	PROPN
chd-110	102	20	.	.	PUNCT
chd-110	103	1	conclusion	conclusion	NOUN
chd-110	103	2	prostate	prostate	NOUN
chd-110	103	3	cancer	cancer	NOUN
chd-110	103	4	research	research	NOUN
chd-110	103	5	is	be	AUX
chd-110	103	6	currently	currently	ADV
chd-110	103	7	at	at	ADP
chd-110	103	8	low	low	ADJ
chd-110	103	9	levels	level	NOUN
chd-110	103	10	of	of	ADP
chd-110	103	11	evidence	evidence	NOUN
chd-110	103	12	in	in	ADP
chd-110	103	13	nigeria	nigeria	PROPN
chd-110	103	14	.	.	PUNCT
chd-110	104	1	as	as	SCONJ
chd-110	104	2	stated	state	VERB
chd-110	104	3	by	by	ADP
chd-110	104	4	prof	prof	PROPN
chd-110	104	5	.	.	PROPN
chd-110	105	1	folakemi	folakemi	PROPN
chd-110	105	2	odedina	odedina	PROPN
chd-110	105	3	,	,	PUNCT
chd-110	105	4	“	"	PUNCT
chd-110	105	5	actionable	actionable	ADJ
chd-110	105	6	research	research	NOUN
chd-110	105	7	is	be	AUX
chd-110	105	8	key	key	ADJ
chd-110	105	9	to	to	ADP
chd-110	105	10	defeating	defeat	VERB
chd-110	105	11	prostate	prostate	NOUN
chd-110	105	12	cancer	cancer	NOUN
chd-110	105	13	”	"	PUNCT
chd-110	105	14	(	(	PUNCT
chd-110	105	15	nigerian	nigerian	ADJ
chd-110	105	16	guardian	guardian	NOUN
chd-110	105	17	,	,	PUNCT
chd-110	105	18	july	july	PROPN
chd-110	105	19	8	8	NUM
chd-110	105	20	,	,	PUNCT
chd-110	105	21	2017	2017	NUM
chd-110	105	22	)	)	PUNCT
chd-110	105	23	.	.	PUNCT
chd-110	106	1	prostate	prostate	NOUN
chd-110	106	2	cancer	cancer	NOUN
chd-110	106	3	researchers	researcher	NOUN
chd-110	106	4	should	should	AUX
chd-110	106	5	make	make	VERB
chd-110	106	6	efforts	effort	NOUN
chd-110	106	7	to	to	PART
chd-110	106	8	conduct	conduct	VERB
chd-110	106	9	and	and	CCONJ
chd-110	106	10	publish	publish	VERB
chd-110	106	11	more	more	ADJ
chd-110	106	12	studies	study	NOUN
chd-110	106	13	especially	especially	ADV
chd-110	106	14	at	at	ADP
chd-110	106	15	higher	high	ADJ
chd-110	106	16	levels	level	NOUN
chd-110	106	17	of	of	ADP
chd-110	106	18	proof	proof	NOUN
chd-110	106	19	like	like	ADP
chd-110	106	20	rcts	rct	NOUN
chd-110	106	21	and	and	CCONJ
chd-110	106	22	metanalysis	metanalysis	NOUN
chd-110	106	23	/	/	SYM
chd-110	106	24	systematic	systematic	ADJ
chd-110	106	25	reviews	review	NOUN
chd-110	106	26	of	of	ADP
chd-110	106	27	rct	rct	PROPN
chd-110	106	28	as	as	ADV
chd-110	106	29	well	well	ADV
chd-110	106	30	as	as	ADP
chd-110	106	31	develop	develop	VERB
chd-110	106	32	treatment	treatment	NOUN
chd-110	106	33	guidelines	guideline	NOUN
chd-110	106	34	for	for	ADP
chd-110	106	35	patients	patient	NOUN
chd-110	106	36	based	base	VERB
chd-110	106	37	on	on	ADP
chd-110	106	38	these	these	DET
chd-110	106	39	higher	high	ADJ
chd-110	106	40	levels	level	NOUN
chd-110	106	41	of	of	ADP
chd-110	106	42	evidence	evidence	NOUN
chd-110	106	43	.	.	PUNCT
chd-110	107	1	it	it	PRON
chd-110	107	2	is	be	AUX
chd-110	107	3	also	also	ADV
chd-110	107	4	pertinent	pertinent	ADJ
chd-110	107	5	that	that	SCONJ
chd-110	107	6	the	the	DET
chd-110	107	7	nigerian	nigerian	ADJ
chd-110	107	8	government	government	NOUN
chd-110	107	9	increases	increase	VERB
chd-110	107	10	its	its	PRON
chd-110	107	11	efforts	effort	NOUN
chd-110	107	12	in	in	ADP
chd-110	107	13	providing	provide	VERB
chd-110	107	14	the	the	DET
chd-110	107	15	support	support	NOUN
chd-110	107	16	needed	need	VERB
chd-110	107	17	on	on	ADP
chd-110	107	18	funding	fund	VERB
chd-110	107	19	cancer	cancer	NOUN
chd-110	107	20	-	-	PUNCT
chd-110	107	21	related	relate	VERB
chd-110	107	22	research	research	NOUN
chd-110	107	23	.	.	PUNCT
chd-110	108	1	the	the	DET
chd-110	108	2	nigerian	nigerian	ADJ
chd-110	108	3	government	government	NOUN
chd-110	108	4	should	should	AUX
chd-110	108	5	also	also	ADV
chd-110	108	6	develop	develop	VERB
chd-110	108	7	and	and	CCONJ
chd-110	108	8	implement	implement	VERB
chd-110	108	9	policies	policy	NOUN
chd-110	108	10	related	relate	VERB
chd-110	108	11	to	to	ADP
chd-110	108	12	increasing	increase	VERB
chd-110	108	13	cancer	cancer	NOUN
chd-110	108	14	research	research	NOUN
chd-110	108	15	funding	funding	NOUN
chd-110	108	16	through	through	ADP
chd-110	108	17	governmental	governmental	ADJ
chd-110	108	18	grants	grant	NOUN
chd-110	108	19	.	.	PUNCT
chd-110	109	1	finally	finally	ADV
chd-110	109	2	,	,	PUNCT
chd-110	109	3	there	there	PRON
chd-110	109	4	needs	need	VERB
chd-110	109	5	to	to	PART
chd-110	109	6	be	be	AUX
chd-110	109	7	increase	increase	NOUN
chd-110	109	8	in	in	ADP
chd-110	109	9	corporate	corporate	ADJ
chd-110	109	10	funding	funding	NOUN
chd-110	109	11	and	and	CCONJ
chd-110	109	12	philanthropic	philanthropic	NOUN
chd-110	109	13	funding	funding	NOUN
chd-110	109	14	for	for	ADP
chd-110	109	15	prostate	prostate	NOUN
chd-110	109	16	cancer	cancer	NOUN
chd-110	109	17	research	research	NOUN
chd-110	109	18	.	.	PUNCT
chd-110	110	1	acknowledgements	acknowledgement	NOUN
chd-110	110	2	we	we	PRON
chd-110	110	3	acknowledge	acknowledge	VERB
chd-110	110	4	ms	ms	PROPN
chd-110	110	5	.	.	PROPN
chd-110	110	6	kimberly	kimberly	PROPN
chd-110	110	7	meza	meza	PROPN
chd-110	110	8	for	for	ADP
chd-110	110	9	her	her	PRON
chd-110	110	10	editorial	editorial	ADJ
chd-110	110	11	review	review	NOUN
chd-110	110	12	conflict	conflict	NOUN
chd-110	110	13	of	of	ADP
chd-110	110	14	interest	interest	NOUN
chd-110	110	15	the	the	DET
chd-110	110	16	authors	author	NOUN
chd-110	110	17	declare	declare	VERB
chd-110	110	18	that	that	SCONJ
chd-110	110	19	no	no	DET
chd-110	110	20	competing	compete	VERB
chd-110	110	21	or	or	CCONJ
chd-110	110	22	conflict	conflict	NOUN
chd-110	110	23	of	of	ADP
chd-110	110	24	interests	interest	NOUN
chd-110	110	25	exists	exist	VERB
chd-110	110	26	.	.	PUNCT
chd-110	111	1	the	the	DET
chd-110	111	2	funders	funder	NOUN
chd-110	111	3	had	have	VERB
chd-110	111	4	no	no	DET
chd-110	111	5	role	role	NOUN
chd-110	111	6	in	in	ADP
chd-110	111	7	study	study	NOUN
chd-110	111	8	design	design	NOUN
chd-110	111	9	,	,	PUNCT
chd-110	111	10	writing	writing	NOUN
chd-110	111	11	of	of	ADP
chd-110	111	12	the	the	DET
chd-110	111	13	manuscript	manuscript	NOUN
chd-110	111	14	,	,	PUNCT
chd-110	111	15	or	or	CCONJ
chd-110	111	16	decision	decision	NOUN
chd-110	111	17	to	to	PART
chd-110	111	18	publish	publish	VERB
chd-110	111	19	.	.	PUNCT
chd-110	112	1	authors	author	NOUN
chd-110	112	2	’	’	PART
chd-110	112	3	contributions	contribution	NOUN
chd-110	112	4	o.a.f	o.a.f	ADV
chd-110	112	5	,	,	PUNCT
chd-110	112	6	a.c.s	a.c.s	PROPN
chd-110	112	7	&	&	CCONJ
chd-110	112	8	f.b	f.b	PROPN
chd-110	112	9	did	do	AUX
chd-110	112	10	the	the	DET
chd-110	112	11	manuscript	manuscript	NOUN
chd-110	112	12	writing	writing	NOUN
chd-110	112	13	and	and	CCONJ
chd-110	112	14	design	design	NOUN
chd-110	112	15	.	.	PUNCT
chd-110	113	1	o.i	o.i	PROPN
chd-110	113	2	,	,	PUNCT
chd-110	113	3	o.o	o.o	PROPN
chd-110	113	4	,	,	PUNCT
chd-110	113	5	a.a	a.a	PROPN
chd-110	113	6	did	do	VERB
chd-110	113	7	the	the	DET
chd-110	113	8	data	data	NOUN
chd-110	113	9	extraction	extraction	NOUN
chd-110	113	10	and	and	CCONJ
chd-110	113	11	literature	literature	NOUN
chd-110	113	12	search	search	NOUN
chd-110	113	13	.	.	PUNCT
chd-110	114	1	f.c	f.c	PROPN
chd-110	114	2	,	,	PUNCT
chd-110	114	3	n.d	n.d	PROPN
chd-110	114	4	,	,	PUNCT
chd-110	114	5	f.o	f.o	PROPN
chd-110	114	6	supervised	supervise	VERB
chd-110	114	7	the	the	DET
chd-110	114	8	project	project	NOUN
chd-110	114	9	.	.	PUNCT
chd-110	115	1	references	reference	NOUN
chd-110	115	2	adeloye	adeloye	ADV
chd-110	115	3	,	,	PUNCT
chd-110	115	4	davies	davy	NOUN
chd-110	115	5	,	,	PUNCT
chd-110	115	6	rotimi	rotimi	PROPN
chd-110	115	7	adedeji	adedeji	PROPN
chd-110	115	8	david	david	PROPN
chd-110	115	9	,	,	PUNCT
chd-110	115	10	adewale	adewale	PROPN
chd-110	115	11	victor	victor	PROPN
chd-110	115	12	aderemi	aderemi	PROPN
chd-110	115	13	,	,	PUNCT
chd-110	115	14	alexander	alexander	PROPN
chd-110	115	15	iseolorunkanmi	iseolorunkanmi	PROPN
chd-110	115	16	,	,	PUNCT
chd-110	115	17	ayo	ayo	PROPN
chd-110	115	18	oyedokun	oyedokun	NOUN
chd-110	115	19	,	,	PUNCT
chd-110	115	20	emeka	emeka	PROPN
chd-110	115	21	e.j	e.j	PROPN
chd-110	115	22	.	.	PROPN
chd-110	115	23	iweala	iweala	PROPN
chd-110	115	24	,	,	PUNCT
chd-110	115	25	nicholas	nicholas	PROPN
chd-110	115	26	omoregbe	omoregbe	NOUN
chd-110	115	27	,	,	PUNCT
chd-110	115	28	and	and	CCONJ
chd-110	115	29	charles	charles	PROPN
chd-110	115	30	k.	k.	PROPN
chd-110	115	31	ayo	ayo	PROPN
chd-110	115	32	.	.	PROPN
chd-110	115	33	2016	2016	NUM
chd-110	115	34	.	.	PUNCT
chd-110	116	1	‘	'	PUNCT
chd-110	116	2	an	an	DET
chd-110	116	3	estimate	estimate	NOUN
chd-110	116	4	of	of	ADP
chd-110	116	5	the	the	DET
chd-110	116	6	incidence	incidence	NOUN
chd-110	116	7	of	of	ADP
chd-110	116	8	prostate	prostate	NOUN
chd-110	116	9	cancer	cancer	NOUN
chd-110	116	10	in	in	ADP
chd-110	116	11	africa	africa	PROPN
chd-110	116	12	:	:	PUNCT
chd-110	116	13	a	a	DET
chd-110	116	14	systematic	systematic	ADJ
chd-110	116	15	review	review	NOUN
chd-110	116	16	and	and	CCONJ
chd-110	116	17	meta	meta	ADJ
chd-110	116	18	-	-	PUNCT
chd-110	116	19	analysis	analysis	NOUN
chd-110	116	20	’	'	PUNCT
chd-110	116	21	.	.	PUNCT
chd-110	117	1	plos	plos	PROPN
chd-110	117	2	one	one	NUM
chd-110	117	3	11	11	NUM
chd-110	117	4	(	(	PUNCT
chd-110	117	5	4	4	NUM
chd-110	117	6	)	)	PUNCT
chd-110	117	7	.	.	PUNCT
chd-110	118	1	https://doi.org/10.1371/journal.pone	https://doi.org/10.1371/journal.pone	PROPN
chd-110	118	2	.	.	PUNCT
chd-110	119	1	0153496	0153496	NUM
chd-110	119	2	.	.	PUNCT
chd-110	120	1	brawley	brawley	PROPN
chd-110	120	2	,	,	PUNCT
chd-110	120	3	otis	otis	PROPN
chd-110	120	4	w.	w.	PROPN
chd-110	120	5	2012	2012	NUM
chd-110	120	6	.	.	PUNCT
chd-110	121	1	‘	'	PUNCT
chd-110	121	2	trends	trend	NOUN
chd-110	121	3	in	in	ADP
chd-110	121	4	prostate	prostate	NOUN
chd-110	121	5	cancer	cancer	NOUN
chd-110	121	6	in	in	ADP
chd-110	121	7	the	the	DET
chd-110	121	8	united	united	PROPN
chd-110	121	9	states	states	PROPN
chd-110	121	10	’	'	PUNCT
chd-110	121	11	.	.	PUNCT
chd-110	122	1	journal	journal	PROPN
chd-110	122	2	of	of	ADP
chd-110	122	3	the	the	DET
chd-110	122	4	national	national	PROPN
chd-110	122	5	cancer	cancer	PROPN
chd-110	122	6	institute	institute	PROPN
chd-110	122	7	monographs	monographs	PROPN
chd-110	122	8	,	,	PUNCT
chd-110	122	9	no	no	INTJ
chd-110	122	10	.	.	NOUN
chd-110	122	11	45	45	NUM
chd-110	122	12	:	:	PUNCT
chd-110	122	13	152–56	152–56	NUM
chd-110	122	14	.	.	PUNCT
chd-110	123	1	https://doi.org/10.1093/	https://doi.org/10.1093/	PROPN
chd-110	123	2	jncimonographs	jncimonographs	PROPN
chd-110	123	3	/	/	SYM
chd-110	123	4	lgs035	lgs035	PROPN
chd-110	123	5	.	.	PUNCT
chd-110	123	6	burns	burn	NOUN
chd-110	123	7	,	,	PUNCT
chd-110	123	8	patricia	patricia	PROPN
chd-110	123	9	b.	b.	PROPN
chd-110	123	10	,	,	PUNCT
chd-110	123	11	rod	rod	VERB
chd-110	123	12	j.	j.	PROPN
chd-110	123	13	rohrich	rohrich	PROPN
chd-110	123	14	,	,	PUNCT
chd-110	123	15	and	and	CCONJ
chd-110	123	16	kevin	kevin	PROPN
chd-110	123	17	c.	c.	PROPN
chd-110	123	18	chung	chung	PROPN
chd-110	123	19	.	.	PUNCT
chd-110	124	1	2011	2011	NUM
chd-110	124	2	.	.	PUNCT
chd-110	125	1	‘	'	PUNCT
chd-110	125	2	the	the	DET
chd-110	125	3	levels	level	NOUN
chd-110	125	4	of	of	ADP
chd-110	125	5	evidence	evidence	NOUN
chd-110	125	6	and	and	CCONJ
chd-110	125	7	their	their	PRON
chd-110	125	8	role	role	NOUN
chd-110	125	9	in	in	ADP
chd-110	125	10	evidence	evidence	NOUN
chd-110	125	11	-	-	PUNCT
chd-110	125	12	based	base	VERB
chd-110	125	13	medicine	medicine	NOUN
chd-110	125	14	’	'	PUNCT
chd-110	125	15	.	.	PUNCT
chd-110	126	1	plastic	plastic	ADJ
chd-110	126	2	and	and	CCONJ
chd-110	126	3	reconstructive	reconstructive	ADJ
chd-110	126	4	surgery	surgery	NOUN
chd-110	126	5	128	128	NUM
chd-110	126	6	(	(	PUNCT
chd-110	126	7	1	1	NUM
chd-110	126	8	):	):	PUNCT
chd-110	126	9	305	305	NUM
chd-110	126	10	–	–	PUNCT
chd-110	126	11	10	10	NUM
chd-110	126	12	.	.	PUNCT
chd-110	127	1	https://doi.org/10.1097/prs.0b013e318219c171	https://doi.org/10.1097/prs.0b013e318219c171	NOUN
chd-110	127	2	.	.	PUNCT
chd-110	128	1	christensen	christensen	PROPN
chd-110	128	2	,	,	PUNCT
chd-110	128	3	michael	michael	PROPN
chd-110	128	4	c	c	PROPN
chd-110	128	5	,	,	PUNCT
chd-110	128	6	alan	alan	PROPN
chd-110	128	7	moskowitz	moskowitz	PROPN
chd-110	128	8	,	,	PUNCT
chd-110	128	9	ardesheer	ardesheer	PROPN
chd-110	128	10	talati	talati	PROPN
chd-110	128	11	,	,	PUNCT
chd-110	128	12	richard	richard	PROPN
chd-110	128	13	r	r	PROPN
chd-110	128	14	nelson	nelson	PROPN
chd-110	128	15	,	,	PUNCT
chd-110	128	16	and	and	CCONJ
chd-110	128	17	nathan	nathan	PROPN
chd-110	128	18	rosenberg	rosenberg	PROPN
chd-110	128	19	.	.	PROPN
chd-110	128	20	2007	2007	NUM
chd-110	128	21	.	.	PUNCT
chd-110	129	1	‘	'	PUNCT
chd-110	129	2	on	on	ADP
chd-110	129	3	the	the	DET
chd-110	129	4	role	role	NOUN
chd-110	129	5	of	of	ADP
chd-110	129	6	randomized	randomized	ADJ
chd-110	129	7	clinical	clinical	ADJ
chd-110	129	8	trials	trial	NOUN
chd-110	129	9	in	in	ADP
chd-110	129	10	medicine	medicine	NOUN
chd-110	129	11	’	'	PUNCT
chd-110	129	12	.	.	PUNCT
chd-110	130	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-110	130	2	e9	e9	PROPN
chd-110	130	3	cancer	cancer	NOUN
chd-110	130	4	health	health	NOUN
chd-110	130	5	disparities	disparity	NOUN
chd-110	130	6	research	research	VERB
chd-110	130	7	economics	economic	NOUN
chd-110	130	8	of	of	ADP
chd-110	130	9	innovation	innovation	NOUN
chd-110	130	10	and	and	CCONJ
chd-110	130	11	new	new	ADJ
chd-110	130	12	technology	technology	NOUN
chd-110	130	13	16	16	NUM
chd-110	130	14	(	(	PUNCT
chd-110	130	15	5	5	NUM
chd-110	130	16	):	):	PUNCT
chd-110	130	17	357	357	NUM
chd-110	130	18	–	–	SYM
chd-110	130	19	70	70	NUM
chd-110	130	20	.	.	PUNCT
chd-110	131	1	https://doi.org/10.1080/10438590600982426	https://doi.org/10.1080/10438590600982426	NOUN
chd-110	131	2	.	.	PUNCT
chd-110	132	1	elima	elima	PROPN
chd-110	132	2	,	,	PUNCT
chd-110	132	3	maria	maria	PROPN
chd-110	132	4	paula	paula	PROPN
chd-110	132	5	curado	curado	PROPN
chd-110	132	6	,	,	PUNCT
chd-110	132	7	olufemi	olufemi	ADJ
chd-110	132	8	ogunbiyi	ogunbiyi	PROPN
chd-110	132	9	,	,	PUNCT
chd-110	132	10	emmanuel	emmanuel	PROPN
chd-110	132	11	oga	oga	PROPN
chd-110	132	12	,	,	PUNCT
chd-110	132	13	toyin	toyin	NOUN
chd-110	132	14	fabowale	fabowale	NOUN
chd-110	132	15	,	,	PUNCT
chd-110	132	16	festus	festus	PROPN
chd-110	132	17	igbinoba	igbinoba	PROPN
chd-110	132	18	,	,	PUNCT
chd-110	132	19	gloria	gloria	PROPN
chd-110	132	20	osubor	osubor	NOUN
chd-110	132	21	,	,	PUNCT
chd-110	132	22	et	et	PROPN
chd-110	132	23	al	al	PROPN
chd-110	132	24	.	.	PROPN
chd-110	132	25	2012	2012	NUM
chd-110	132	26	.	.	PUNCT
chd-110	133	1	‘	'	PUNCT
chd-110	133	2	cancer	cancer	NOUN
chd-110	133	3	incidence	incidence	NOUN
chd-110	133	4	in	in	ADP
chd-110	133	5	nigeria	nigeria	PROPN
chd-110	133	6	:	:	PUNCT
chd-110	133	7	a	a	DET
chd-110	133	8	report	report	NOUN
chd-110	133	9	from	from	ADP
chd-110	133	10	population	population	NOUN
chd-110	133	11	-	-	PUNCT
chd-110	133	12	based	base	VERB
chd-110	133	13	cancer	cancer	NOUN
chd-110	133	14	registries	registry	NOUN
chd-110	133	15	.	.	PUNCT
chd-110	133	16	’	'	PUNCT
chd-110	134	1	cancer	cancer	NOUN
chd-110	134	2	epidemiology	epidemiology	NOUN
chd-110	134	3	36	36	NUM
chd-110	134	4	(	(	PUNCT
chd-110	134	5	5	5	NUM
chd-110	134	6	)	)	PUNCT
chd-110	134	7	.	.	PUNCT
chd-110	135	1	nih	nih	PROPN
chd-110	135	2	public	public	ADJ
chd-110	135	3	access	access	NOUN
chd-110	135	4	:	:	PUNCT
chd-110	135	5	e271	e271	NOUN
chd-110	135	6	-	-	SYM
chd-110	135	7	8	8	NUM
chd-110	135	8	.	.	PUNCT
chd-110	136	1	https://doi.org/10.1016/j.canep.2012.04.007	https://doi.org/10.1016/j.canep.2012.04.007	X
chd-110	136	2	.	.	PUNCT
chd-110	137	1	ferlay	ferlay	NOUN
chd-110	137	2	,	,	PUNCT
chd-110	137	3	jacques	jacques	PROPN
chd-110	137	4	,	,	PUNCT
chd-110	137	5	isabelle	isabelle	PROPN
chd-110	137	6	soerjomataram	soerjomataram	PROPN
chd-110	137	7	,	,	PUNCT
chd-110	137	8	rajesh	rajesh	PROPN
chd-110	137	9	dikshit	dikshit	PROPN
chd-110	137	10	,	,	PUNCT
chd-110	137	11	sultan	sultan	PROPN
chd-110	137	12	eser	eser	PROPN
chd-110	137	13	,	,	PUNCT
chd-110	137	14	colin	colin	PROPN
chd-110	137	15	mathers	mathers	PROPN
chd-110	137	16	,	,	PUNCT
chd-110	137	17	marise	marise	NOUN
chd-110	137	18	rebelo	rebelo	NOUN
chd-110	137	19	,	,	PUNCT
chd-110	137	20	donald	donald	PROPN
chd-110	137	21	maxwell	maxwell	PROPN
chd-110	137	22	parkin	parkin	PROPN
chd-110	137	23	,	,	PUNCT
chd-110	137	24	david	david	PROPN
chd-110	137	25	forman	forman	PROPN
chd-110	137	26	,	,	PUNCT
chd-110	137	27	and	and	CCONJ
chd-110	137	28	freddie	freddie	PROPN
chd-110	137	29	bray	bray	PROPN
chd-110	137	30	.	.	PUNCT
chd-110	138	1	2015	2015	NUM
chd-110	138	2	.	.	PUNCT
chd-110	139	1	‘	'	PUNCT
chd-110	139	2	cancer	cancer	NOUN
chd-110	139	3	incidence	incidence	NOUN
chd-110	139	4	and	and	CCONJ
chd-110	139	5	mortality	mortality	NOUN
chd-110	139	6	worldwide	worldwide	ADV
chd-110	139	7	 	 	SPACE
chd-110	139	8	:	:	PUNCT
chd-110	139	9	sources	source	NOUN
chd-110	139	10	,	,	PUNCT
chd-110	139	11	methods	method	NOUN
chd-110	139	12	and	and	CCONJ
chd-110	139	13	major	major	ADJ
chd-110	139	14	patterns	pattern	NOUN
chd-110	139	15	in	in	ADP
chd-110	139	16	globocan	globocan	PROPN
chd-110	139	17	2012	2012	NUM
chd-110	139	18	’	'	PUNCT
chd-110	139	19	.	.	PUNCT
chd-110	140	1	int	int	PROPN
chd-110	140	2	j	j	PROPN
chd-110	140	3	cancer	cancer	NOUN
chd-110	140	4	386	386	NUM
chd-110	140	5	(	(	PUNCT
chd-110	140	6	136	136	NUM
chd-110	140	7	(	(	PUNCT
chd-110	140	8	5	5	NUM
chd-110	140	9	)	)	PUNCT
chd-110	140	10	):	):	PUNCT
chd-110	140	11	359–86	359–86	NUM
chd-110	140	12	.	.	PUNCT
chd-110	141	1	https://doi.org/10.1002/ijc.29210	https://doi.org/10.1002/ijc.29210	NOUN
chd-110	141	2	.	.	PUNCT
chd-110	142	1	hm	hm	INTJ
chd-110	142	2	government	government	NOUN
chd-110	142	3	.	.	PUNCT
chd-110	143	1	2016	2016	NUM
chd-110	143	2	.	.	PUNCT
chd-110	144	1	‘	'	PUNCT
chd-110	144	2	the	the	DET
chd-110	144	3	allocation	allocation	NOUN
chd-110	144	4	of	of	ADP
chd-110	144	5	science	science	NOUN
chd-110	144	6	and	and	CCONJ
chd-110	144	7	research	research	NOUN
chd-110	144	8	funding	funding	NOUN
chd-110	144	9	’	'	PUNCT
chd-110	144	10	.	.	PUNCT
chd-110	145	1	gov.uk	gov.uk	PROPN
chd-110	145	2	,	,	PUNCT
chd-110	145	3	no	no	INTJ
chd-110	145	4	.	.	PUNCT
chd-110	145	5	march	march	PROPN
chd-110	145	6	:	:	PUNCT
chd-110	145	7	1–57	1–57	PROPN
chd-110	145	8	.	.	PUNCT
chd-110	146	1	james	james	PROPN
chd-110	146	2	,	,	PUNCT
chd-110	146	3	nicholas	nicholas	PROPN
chd-110	146	4	david	david	PROPN
chd-110	146	5	,	,	PUNCT
chd-110	146	6	matthew	matthew	PROPN
chd-110	146	7	robert	robert	PROPN
chd-110	146	8	sydes	sydes	PROPN
chd-110	146	9	,	,	PUNCT
chd-110	146	10	malcolm	malcolm	PROPN
chd-110	146	11	david	david	PROPN
chd-110	146	12	mason	mason	PROPN
chd-110	146	13	,	,	PUNCT
chd-110	146	14	noel	noel	PROPN
chd-110	146	15	w	w	PROPN
chd-110	146	16	clarke	clarke	PROPN
chd-110	146	17	,	,	PUNCT
chd-110	146	18	david	david	PROPN
chd-110	146	19	paul	paul	PROPN
chd-110	146	20	dearnaley	dearnaley	PROPN
chd-110	146	21	,	,	PUNCT
chd-110	146	22	melissa	melissa	PROPN
chd-110	146	23	ruth	ruth	PROPN
chd-110	146	24	spears	spear	NOUN
chd-110	146	25	,	,	PUNCT
chd-110	146	26	robin	robin	PROPN
chd-110	146	27	millman	millman	PROPN
chd-110	146	28	,	,	PUNCT
chd-110	146	29	et	et	PROPN
chd-110	146	30	al	al	PROPN
chd-110	146	31	.	.	PROPN
chd-110	146	32	2015	2015	NUM
chd-110	146	33	.	.	PUNCT
chd-110	147	1	‘	'	PUNCT
chd-110	147	2	docetaxel	docetaxel	NOUN
chd-110	147	3	and/or	and/or	CCONJ
chd-110	147	4	zoledronic	zoledronic	ADJ
chd-110	147	5	acid	acid	NOUN
chd-110	147	6	for	for	ADP
chd-110	147	7	hormone	hormone	NOUN
chd-110	147	8	-	-	PUNCT
chd-110	147	9	naïve	naïve	ADJ
chd-110	147	10	prostate	prostate	NOUN
chd-110	147	11	cancer	cancer	NOUN
chd-110	147	12	:	:	PUNCT
chd-110	147	13	first	first	ADJ
chd-110	147	14	overall	overall	ADJ
chd-110	147	15	survival	survival	NOUN
chd-110	147	16	results	result	NOUN
chd-110	147	17	from	from	ADP
chd-110	147	18	stampede	stampede	NOUN
chd-110	147	19	(	(	PUNCT
chd-110	147	20	nct00268476	nct00268476	ADJ
chd-110	147	21	)	)	PUNCT
chd-110	147	22	.	.	PUNCT
chd-110	147	23	’	'	PUNCT
chd-110	148	1	j	j	PROPN
chd-110	148	2	clin	clin	PROPN
chd-110	148	3	oncol	oncol	PROPN
chd-110	148	4	33	33	NUM
chd-110	148	5	.	.	PUNCT
chd-110	149	1	ocebm	ocebm	PROPN
chd-110	149	2	levels	level	NOUN
chd-110	149	3	of	of	ADP
chd-110	149	4	evidence	evidence	NOUN
chd-110	149	5	working	working	NOUN
chd-110	149	6	group	group	NOUN
chd-110	149	7	,	,	PUNCT
chd-110	149	8	ocebm	ocebm	PROPN
chd-110	149	9	,	,	PUNCT
chd-110	149	10	jeremy	jeremy	PROPN
chd-110	149	11	howick	howick	PROPN
chd-110	149	12	,	,	PUNCT
chd-110	149	13	iain	iain	PROPN
chd-110	149	14	chalmers	chalmers	PROPN
chd-110	149	15	(	(	PUNCT
chd-110	149	16	james	james	PROPN
chd-110	149	17	lind	lind	PROPN
chd-110	149	18	library	library	PROPN
chd-110	149	19	)	)	PUNCT
chd-110	149	20	,	,	PUNCT
chd-110	149	21	paul	paul	PROPN
chd-110	149	22	glasziou	glasziou	PROPN
chd-110	149	23	,	,	PUNCT
chd-110	149	24	trish	trish	PROPN
chd-110	149	25	greenhalgh	greenhalgh	PROPN
chd-110	149	26	,	,	PUNCT
chd-110	149	27	carl	carl	PROPN
chd-110	149	28	heneghan	heneghan	PROPN
chd-110	149	29	,	,	PUNCT
chd-110	149	30	alessandro	alessandro	PROPN
chd-110	149	31	liberati	liberati	PROPN
chd-110	149	32	,	,	PUNCT
chd-110	149	33	et	et	PROPN
chd-110	149	34	al	al	PROPN
chd-110	149	35	.	.	PROPN
chd-110	149	36	2011	2011	NUM
chd-110	149	37	.	.	PUNCT
chd-110	150	1	‘	'	PUNCT
chd-110	150	2	the	the	DET
chd-110	150	3	oxford	oxford	ADJ
chd-110	150	4	levels	level	NOUN
chd-110	150	5	of	of	ADP
chd-110	150	6	evidence	evidence	NOUN
chd-110	150	7	2	2	NUM
chd-110	150	8	’	'	PUNCT
chd-110	150	9	.	.	PUNCT
chd-110	151	1	oxford	oxford	PROPN
chd-110	151	2	centre	centre	NOUN
chd-110	151	3	for	for	ADP
chd-110	151	4	evidence	evidence	NOUN
chd-110	151	5	-	-	PUNCT
chd-110	151	6	based	base	VERB
chd-110	151	7	medicine	medicine	NOUN
chd-110	151	8	1	1	NUM
chd-110	151	9	(	(	PUNCT
chd-110	151	10	version	version	NOUN
chd-110	151	11	):	):	PUNCT
chd-110	151	12	5653	5653	NUM
chd-110	151	13	.	.	PUNCT
chd-110	152	1	odedina	odedina	PROPN
chd-110	152	2	,	,	PUNCT
chd-110	152	3	folakemi	folakemi	PROPN
chd-110	152	4	t.	t.	PROPN
chd-110	152	5	,	,	PUNCT
chd-110	152	6	titilola	titilola	PROPN
chd-110	152	7	o.	o.	PROPN
chd-110	152	8	akinremi	akinremi	PROPN
chd-110	152	9	,	,	PUNCT
chd-110	152	10	frank	frank	PROPN
chd-110	152	11	chinegwundoh	chinegwundoh	PROPN
chd-110	152	12	,	,	PUNCT
chd-110	152	13	robin	robin	PROPN
chd-110	152	14	roberts	roberts	PROPN
chd-110	152	15	,	,	PUNCT
chd-110	152	16	daohai	daohai	PROPN
chd-110	152	17	yu	yu	PROPN
chd-110	152	18	,	,	PUNCT
chd-110	152	19	r.	r.	PROPN
chd-110	152	20	renee	renee	PROPN
chd-110	152	21	reams	reams	PROPN
chd-110	152	22	,	,	PUNCT
chd-110	152	23	matthew	matthew	PROPN
chd-110	152	24	l.	l.	PROPN
chd-110	152	25	freedman	freedman	PROPN
chd-110	152	26	,	,	PUNCT
chd-110	152	27	brian	brian	PROPN
chd-110	152	28	rivers	rivers	PROPN
chd-110	152	29	,	,	PUNCT
chd-110	152	30	b.	b.	PROPN
chd-110	152	31	lee	lee	PROPN
chd-110	152	32	green	green	PROPN
chd-110	152	33	,	,	PUNCT
chd-110	152	34	and	and	CCONJ
chd-110	152	35	nagi	nagi	PROPN
chd-110	152	36	kumar	kumar	PROPN
chd-110	152	37	.	.	PROPN
chd-110	152	38	2009	2009	NUM
chd-110	152	39	.	.	PUNCT
chd-110	153	1	‘	'	PUNCT
chd-110	153	2	prostate	prostate	NOUN
chd-110	153	3	cancer	cancer	NOUN
chd-110	153	4	disparities	disparity	NOUN
chd-110	153	5	in	in	ADP
chd-110	153	6	black	black	ADJ
chd-110	153	7	men	man	NOUN
chd-110	153	8	of	of	ADP
chd-110	153	9	african	african	ADJ
chd-110	153	10	descent	descent	NOUN
chd-110	153	11	:	:	PUNCT
chd-110	153	12	a	a	DET
chd-110	153	13	comparative	comparative	ADJ
chd-110	153	14	literature	literature	NOUN
chd-110	153	15	review	review	NOUN
chd-110	153	16	of	of	ADP
chd-110	153	17	prostate	prostate	NOUN
chd-110	153	18	cancer	cancer	NOUN
chd-110	153	19	burden	burden	NOUN
chd-110	153	20	among	among	ADP
chd-110	153	21	black	black	ADJ
chd-110	153	22	men	man	NOUN
chd-110	153	23	in	in	ADP
chd-110	153	24	the	the	DET
chd-110	153	25	united	united	PROPN
chd-110	153	26	states	states	PROPN
chd-110	153	27	,	,	PUNCT
chd-110	153	28	caribbean	caribbean	PROPN
chd-110	153	29	,	,	PUNCT
chd-110	153	30	united	united	ADJ
chd-110	153	31	kingdom	kingdom	NOUN
chd-110	153	32	,	,	PUNCT
chd-110	153	33	and	and	CCONJ
chd-110	153	34	west	west	PROPN
chd-110	153	35	africa	africa	PROPN
chd-110	153	36	’	'	PUNCT
chd-110	153	37	.	.	PUNCT
chd-110	154	1	in	in	ADP
chd-110	154	2	infectious	infectious	ADJ
chd-110	154	3	agents	agent	NOUN
chd-110	154	4	and	and	CCONJ
chd-110	154	5	cancer	cancer	NOUN
chd-110	154	6	.	.	PUNCT
chd-110	155	1	vol	vol	NOUN
chd-110	155	2	.	.	PROPN
chd-110	156	1	4	4	NUM
chd-110	156	2	.	.	PUNCT
chd-110	157	1	https://doi.org/10.1186/1750-9378-4-s1-s2	https://doi.org/10.1186/1750-9378-4-s1-s2	PROPN
chd-110	157	2	.	.	PUNCT
chd-110	157	3	sackett	sackett	PROPN
chd-110	157	4	,	,	PUNCT
chd-110	157	5	d.	d.	PROPN
chd-110	157	6	,	,	PUNCT
chd-110	157	7	w.	w.	PROPN
chd-110	157	8	rosenberg	rosenberg	PROPN
chd-110	157	9	,	,	PUNCT
chd-110	157	10	j.	j.	PROPN
chd-110	157	11	gray	gray	PROPN
chd-110	157	12	,	,	PUNCT
chd-110	157	13	r.	r.	PROPN
chd-110	157	14	haynes	haynes	PROPN
chd-110	157	15	,	,	PUNCT
chd-110	157	16	and	and	CCONJ
chd-110	157	17	w.	w.	PROPN
chd-110	157	18	richardson	richardson	PROPN
chd-110	157	19	.	.	PUNCT
chd-110	157	20	1996	1996	NUM
chd-110	157	21	.	.	PUNCT
chd-110	158	1	‘	'	PUNCT
chd-110	158	2	evidence	evidence	NOUN
chd-110	158	3	based	base	VERB
chd-110	158	4	medicine	medicine	NOUN
chd-110	158	5	:	:	PUNCT
chd-110	158	6	what	what	PRON
chd-110	158	7	it	it	PRON
chd-110	158	8	is	be	AUX
chd-110	158	9	and	and	CCONJ
chd-110	158	10	what	what	PRON
chd-110	158	11	it	it	PRON
chd-110	158	12	is	be	AUX
chd-110	158	13	n’t	not	PART
chd-110	158	14	’	'	PUNCT
chd-110	158	15	.	.	PUNCT
chd-110	159	1	bmj	bmj	PROPN
chd-110	159	2	312	312	NUM
chd-110	159	3	:	:	PUNCT
chd-110	159	4	71–72	71–72	NUM
chd-110	159	5	.	.	PUNCT
chd-110	159	6	https://doi.org/	https://doi.org/	PROPN
chd-110	159	7	10.1136	10.1136	NUM
chd-110	159	8	/	/	SYM
chd-110	159	9	bmj.312.7023.71	bmj.312.7023.71	NOUN
chd-110	159	10	.	.	PUNCT
chd-110	160	1	sargent	sargent	PROPN
chd-110	160	2	,	,	PUNCT
chd-110	160	3	john	john	PROPN
chd-110	160	4	f	f	PROPN
chd-110	160	5	,	,	PUNCT
chd-110	160	6	judith	judith	PROPN
chd-110	160	7	a	a	DET
chd-110	160	8	johnson	johnson	PROPN
chd-110	160	9	,	,	PUNCT
chd-110	160	10	jim	jim	PROPN
chd-110	160	11	monke	monke	PROPN
chd-110	160	12	,	,	PUNCT
chd-110	160	13	daniel	daniel	PROPN
chd-110	160	14	morgan	morgan	PROPN
chd-110	160	15	,	,	PUNCT
chd-110	160	16	and	and	CCONJ
chd-110	160	17	harold	harold	PROPN
chd-110	160	18	f	f	PROPN
chd-110	160	19	upton	upton	PROPN
chd-110	160	20	.	.	PROPN
chd-110	160	21	2017	2017	NUM
chd-110	160	22	.	.	PUNCT
chd-110	161	1	‘	'	PUNCT
chd-110	161	2	federal	federal	ADJ
chd-110	161	3	research	research	NOUN
chd-110	161	4	and	and	CCONJ
chd-110	161	5	development	development	NOUN
chd-110	161	6	funding	funding	NOUN
chd-110	161	7	:	:	PUNCT
chd-110	161	8	fy2017	fy2017	PROPN
chd-110	161	9	specialist	specialist	NOUN
chd-110	161	10	in	in	ADP
chd-110	161	11	biomedical	biomedical	ADJ
chd-110	161	12	policy	policy	NOUN
chd-110	161	13	specialist	specialist	NOUN
chd-110	161	14	in	in	ADP
chd-110	161	15	agricultural	agricultural	ADJ
chd-110	161	16	policy	policy	NOUN
chd-110	161	17	analyst	analyst	NOUN
chd-110	161	18	in	in	ADP
chd-110	161	19	natural	natural	ADJ
chd-110	161	20	resources	resource	NOUN
chd-110	161	21	policy	policy	NOUN
chd-110	161	22	’	'	PUNCT
chd-110	161	23	.	.	PUNCT
chd-110	162	1	sedgwick	sedgwick	PROPN
chd-110	162	2	,	,	PUNCT
chd-110	162	3	philip	philip	PROPN
chd-110	162	4	.	.	PUNCT
chd-110	162	5	2014	2014	NUM
chd-110	162	6	.	.	PUNCT
chd-110	163	1	‘	'	PUNCT
chd-110	163	2	cross	cross	VERB
chd-110	163	3	sectional	sectional	ADJ
chd-110	163	4	studies	study	NOUN
chd-110	163	5	:	:	PUNCT
chd-110	163	6	advantages	advantage	NOUN
chd-110	163	7	and	and	CCONJ
chd-110	163	8	disadvantages	disadvantage	NOUN
chd-110	163	9	’	'	PUNCT
chd-110	163	10	.	.	PUNCT
chd-110	164	1	bmj	bmj	PROPN
chd-110	164	2	(	(	PUNCT
chd-110	164	3	online	online	ADJ
chd-110	164	4	)	)	PUNCT
chd-110	164	5	.	.	PUNCT
chd-110	165	1	https://doi.org/	https://doi.org/	ADP
chd-110	165	2	10.1136	10.1136	NUM
chd-110	165	3	/	/	SYM
chd-110	165	4	bmj.g2276	bmj.g2276	NOUN
chd-110	165	5	.	.	PUNCT
chd-110	166	1	shenoy	shenoy	PROPN
chd-110	166	2	,	,	PUNCT
chd-110	166	3	divya	divya	NOUN
chd-110	166	4	,	,	PUNCT
chd-110	166	5	satyaseelan	satyaseelan	NOUN
chd-110	166	6	packianathan	packianathan	PROPN
chd-110	166	7	,	,	PUNCT
chd-110	166	8	allen	allen	PROPN
chd-110	166	9	m.	m.	PROPN
chd-110	166	10	chen	chen	PROPN
chd-110	166	11	,	,	PUNCT
chd-110	166	12	and	and	CCONJ
chd-110	166	13	srinivasan	srinivasan	PROPN
chd-110	166	14	vijayakumar	vijayakumar	PROPN
chd-110	166	15	.	.	PROPN
chd-110	166	16	2016	2016	NUM
chd-110	166	17	.	.	PUNCT
chd-110	167	1	‘	'	PUNCT
chd-110	167	2	do	do	AUX
chd-110	167	3	african	african	ADJ
chd-110	167	4	-	-	PUNCT
chd-110	167	5	american	american	ADJ
chd-110	167	6	men	man	NOUN
chd-110	167	7	need	need	VERB
chd-110	167	8	separate	separate	ADJ
chd-110	167	9	prostate	prostate	NOUN
chd-110	167	10	cancer	cancer	NOUN
chd-110	167	11	screening	screen	VERB
chd-110	167	12	guidelines	guideline	NOUN
chd-110	167	13	?	?	PUNCT
chd-110	167	14	’	'	PUNCT
chd-110	167	15	bmc	bmc	ADJ
chd-110	167	16	urology	urology	NOUN
chd-110	167	17	16	16	NUM
chd-110	167	18	(	(	PUNCT
chd-110	167	19	1	1	NUM
chd-110	167	20	)	)	PUNCT
chd-110	167	21	.	.	PUNCT
chd-110	168	1	https://doi.org/10.1186/s12894-0160137-7	https://doi.org/10.1186/s12894-0160137-7	PROPN
chd-110	168	2	.	.	PUNCT
chd-110	169	1	sweeney	sweeney	PROPN
chd-110	169	2	,	,	PUNCT
chd-110	169	3	christopher	christopher	PROPN
chd-110	169	4	j.	j.	PROPN
chd-110	169	5	,	,	PUNCT
chd-110	169	6	yu	yu	PROPN
chd-110	169	7	-	-	PROPN
chd-110	169	8	hui	hui	PROPN
chd-110	169	9	chen	chen	PROPN
chd-110	169	10	,	,	PUNCT
chd-110	169	11	michael	michael	PROPN
chd-110	169	12	carducci	carducci	PROPN
chd-110	169	13	,	,	PUNCT
chd-110	169	14	glenn	glenn	PROPN
chd-110	169	15	liu	liu	PROPN
chd-110	169	16	,	,	PUNCT
chd-110	169	17	david	david	PROPN
chd-110	169	18	f.	f.	PROPN
chd-110	169	19	jarrard	jarrard	PROPN
chd-110	169	20	,	,	PUNCT
chd-110	169	21	mario	mario	PROPN
chd-110	169	22	eisenberger	eisenberger	PROPN
chd-110	169	23	,	,	PUNCT
chd-110	169	24	yu	yu	PROPN
chd-110	169	25	-	-	PUNCT
chd-110	169	26	ning	ning	PROPN
chd-110	169	27	wong	wong	PROPN
chd-110	169	28	,	,	PUNCT
chd-110	169	29	et	et	PROPN
chd-110	169	30	al	al	PROPN
chd-110	169	31	.	.	PROPN
chd-110	169	32	2015	2015	NUM
chd-110	169	33	.	.	PUNCT
chd-110	170	1	‘	'	PUNCT
chd-110	170	2	chemohormonal	chemohormonal	ADJ
chd-110	170	3	therapy	therapy	NOUN
chd-110	170	4	in	in	ADP
chd-110	170	5	metastatic	metastatic	ADJ
chd-110	170	6	hormone	hormone	NOUN
chd-110	170	7	-	-	PUNCT
chd-110	170	8	sensitive	sensitive	ADJ
chd-110	170	9	prostate	prostate	NOUN
chd-110	170	10	cancer	cancer	NOUN
chd-110	170	11	’	'	PUNCT
chd-110	170	12	.	.	PUNCT
chd-110	171	1	new	new	PROPN
chd-110	171	2	england	england	PROPN
chd-110	171	3	journal	journal	PROPN
chd-110	171	4	of	of	ADP
chd-110	171	5	medicine	medicine	NOUN
chd-110	171	6	373	373	NUM
chd-110	171	7	(	(	PUNCT
chd-110	171	8	8)	8)	NUM
chd-110	171	9	:	:	PUNCT
chd-110	171	10	737–46	737–46	NUM
chd-110	171	11	.	.	PUNCT
chd-110	172	1	https://doi.org/10.1056/nejmoa1503747	https://doi.org/10.1056/nejmoa1503747	PROPN
chd-110	172	2	.	.	PUNCT
chd-110	173	1	tetfund	tetfund	PROPN
chd-110	173	2	.	.	PUNCT
chd-110	174	1	2014	2014	NUM
chd-110	174	2	.	.	PUNCT
chd-110	175	1	‘	'	PUNCT
chd-110	175	2	guideline	guideline	NOUN
chd-110	175	3	for	for	ADP
chd-110	175	4	accessing	access	VERB
chd-110	175	5	tetfund	tetfund	ADJ
chd-110	175	6	national	national	ADJ
chd-110	175	7	research	research	NOUN
chd-110	175	8	fund	fund	PROPN
chd-110	175	9	tertiary	tertiary	ADJ
chd-110	175	10	education	education	PROPN
chd-110	175	11	trust	trust	NOUN
chd-110	175	12	fund	fund	NOUN
chd-110	175	13	(	(	PUNCT
chd-110	175	14	tetfund	tetfund	NOUN
chd-110	175	15	)	)	PUNCT
chd-110	175	16	publication	publication	NOUN
chd-110	175	17	’	'	PUNCT
chd-110	175	18	,	,	PUNCT
chd-110	175	19	1–53	1–53	NOUN
chd-110	175	20	.	.	PUNCT